

Structure-Based Design of Selective Fat Mass- and Obesity-Associated Protein (FTO) Inhibitors

Shifali Shishodia, Marina Demetriades, Dong Zhang, Nok Yin Tam, Pratheesh Maheswaran, Caitlin Clunie-O'Connor, Anthony Tumber, Ivanhoe K. H. Leung, Yi Min Ng, Thomas M. Leissing, Afaf H. El-Sagheer, Eidarus Salah, Tom Brown, Wei Shen Aik,* Michael A. McDonough,* and Christopher J. Schofield*



Cite This: <https://doi.org/10.1021/acs.jmedchem.1c01204>



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

ABSTRACT: FTO catalyzes the Fe(II)- and 2-oxoglutarate (2OG)-dependent modification of nucleic acids, including the demethylation of *N*⁶-methyladenosine (*m*⁶A) in mRNA. FTO is a proposed target for anti-cancer therapy. Using information from crystal structures of FTO complexed with 2OG and substrate mimics, we designed and synthesized two series of FTO inhibitors, which were characterized by turnover and binding assays, and by X-ray crystallography with FTO and the related bacterial enzyme AlkB. A potent inhibitor employing binding interactions spanning both 2OG and substrate binding sites of FTO was identified. Selectivity over other clinically targeted 2OG oxygenases was demonstrated, including with respect to the hypoxia-inducible factor prolyl and asparaginyl hydroxylases (PHD2 and FIH) and selected JmjC histone demethylases (KDMs). The results illustrate how a structure-based design can enable the identification of potent and selective 2OG oxygenase inhibitors and will be useful for the development of FTO inhibitors for use *in vivo*.



INTRODUCTION

The fat mass- and obesity-associated protein (FTO) is an Fe(II)- and 2-oxoglutarate (2OG)-dependent oxygenase that catalyzes the oxidation of *N*-methyl groups in nucleic acids, and, in particular, of *N*⁶-methyladenosine (*m*⁶A) in RNA.^{1–3} FTO is a potential medicinal chemistry target due to its roles in obesity and cancer. Single nucleotide polymorphisms in an intron of the *fto* gene are reported to be associated with body weight and type II diabetes in genome-wide association studies.^{4,5} More recent studies have reported roles for FTO in *m*⁶A regulation and cancers, including acute myeloid leukemia and glioblastoma.^{6–11} Precisely, how the role of FTO in RNA oxidation is linked to disease is uncertain. There is thus an unmet need to develop small-molecule probes to complement genetic studies and explore its potential as a therapeutic target. FTO is one of 60–70 human 2OG oxygenases, some of which are medicinal chemistry targets, for example, the hypoxia-inducible factor prolyl hydroxylases (PHD 1–3) and selected JmjC *N*^ε-methyllysine histone demethylases (KDMs).^{12,13} PHD inhibitors have been approved for the treatment of anemia in chronic kidney disease, though there have been concerns regarding their safety.¹⁴ Human nucleic acid oxygenases (NAOXs), such as FTO, are a substantial subset of 2OG oxygenases (>10 enzymes). NAOXs include

eight AlkB homologues (ALKBH 1–8), some of which are involved in DNA damage repair (e.g., ALKBH2) and RNA oxidation (e.g., FTO and ALKBH5) and the Ten Eleven Translocation enzymes (TET1–3), which catalyze sequential oxidations of the methyl group of 5-methylcytosine.^{15,16} FTO catalyzes hydroxylation which can lead to demethylation of *N*-methyl groups on single-stranded RNA and DNA substrates (Figure 1A), including *N*³-methylthymidine (*m*³T), *N*³-methyluridine (*m*³U), *m*⁶A, and *N*⁶,2'-O-dimethyladenosine (*m*⁶Am).^{1–3,17} The lifetime of the nascent *N*-hydroxymethylated products/intermediates varies depending on the nucleobase undergoing oxidation, leading to the proposal that in some circumstances they may be biologically relevant.^{17–19}

There are some reports of FTO inhibition, including by known inhibitors of 2OG oxygenases, such as PHD inhibitors (Figure S1).^{6,7,20–26} We have reported crystallographic and *in* 63

Received: July 6, 2021




Figure 1. (A) Schematic representation of FTO-catalyzed reactions. (B) Reported FTO inhibitors with IC₅₀²⁶ values against FTO (determined using an LC assay with the m³T nucleoside as a substrate).²⁶

in vitro inhibition studies of FTO with known 2OG oxygenase inhibitors including 2OG competitors/analogues (2–4) and rhein (1) (Figure 1B).^{26,27} The most potent FTO inhibitor identified, FG-2216 (2, IC₅₀ 3 μM), is a PHD inhibitor.²⁸ Treatment of mice with FG-2216 (2) led to reduced bone mineral density and altered adipose tissue density distribution without affecting body weight or respiratory exchange ratio.²⁹ Structures of FTO in the complex with 3 (FTO IC₅₀ 3.3 μM) and 4 (FTO IC₅₀ 15 μM) were also obtained.²⁶ 3 was reported as a broad spectrum inhibitor of the JmjC histone lysine demethylases (KDM2A, 3A, 4A-E, 5C, 6A, and B, 7B: IC₅₀ 0.2–25 μM) and was also reported to inhibit the bacterial NAOX AlkB (IC₅₀ 3.4 μM).^{26,30,31} The reported FTO inhibitors thus likely do not have the potency or selectivity required for *in vivo* target validation of FTO. Here, we report the use of structural knowledge of how FTO binds 2OG and substrate to design potent and, at least partially selective, FTO inhibitors.

RESULTS

During 2OG oxygenase catalysis, binding of 2OG in a bidentate manner to the active site Fe(II) is followed by that of the substrate, and then dioxygen.¹² One strategy in 2OG oxygenase inhibitor design has been to covalently link a non-reactive 2OG mimetic with a group occupying the substrate binding site, so yielding more potent and selective inhibitors than the independent fragments.^{32,33} Unlike 2–5, which bind in the 2OG binding pocket of FTO, rhein (1) occupies the nucleobase binding site.²⁶ A comparison of the FTO and 4 (a glycol-hydroxypyridine 2OG mimic) and FTO and rhein (1)²⁶ structural complexes indicates that the hydroxypyridinyl ring of

4 is proximate to the anthraquinone ring of rhein (1), which binds competitively with the substrate nucleobase (Figures 2A and S2). Based on this analysis, we designed and synthesized a series of derivatives of 4 (Table 1) predicted to extend into the substrate binding site by functionalization at the C-6 position (13a–d) (Figure 2A, Scheme 1). 3-Hydroxypicolinonitrile was used as the starting material for C-6 derivatization of 4. C-6 halogenation of the pyridine ring of hydroxypicolinonitrile, followed by hydrolysis of the nitrile gave 6-bromo-3-hydroxypicolinic acid (7), which was coupled with a protected glycine amide (glycine *tert*-butyl ester hydrochloride or glycine phenyl ester hydrochloride). The resulting compounds were coupled to different aryl rings by Suzuki coupling, then deprotected to give the desired acids (13a–d and 14a–i).

We initially tested the *in vitro* inhibitory activity of 13a–d against FTO (1.2 μM) using a reported liquid chromatography (LC)-based assay employing the m³T nucleoside as a substrate.²⁶ 13a (IC₅₀ 35 ± 1 μM), with a phenyl ring at C-6 was slightly less potent than 4 (IC₅₀ 15 μM) against FTO. 13a and 13b (IC₅₀ 15 ± 1 μM) had potencies similar to that of 4 against PHD2 and FTO; however, 13a showed little or no inhibition (IC₅₀ > 100 μM) toward the 2OG-dependent JmjC KDMs, KDM3A, KDM4C, and KDM6B and showed limited activity (IC₅₀s 34–88 μM) toward KDM5A, B, C, and KDM2A (Tables 1 and S2). The introduction of a biphenyl ring at C-6 of the pyridine ring (13b) resulted in moderate FTO inhibition (IC₅₀ 15 ± 1 μM), while manifesting an increased inhibition of the other tested 2OG oxygenases (PHD2, FIH, KDM3A, KDM4C, KDM6B, KDM5A, KDM5B, KDM5C, KDM5D, and KDM2A) compared to 13a (Tables 1 and S2). Substitution at C-6 of the pyridine with 1-







Figure 2. Structure-based FTO inhibitor design. (A) View of the active site from a crystal structure of FTO Δ 31 (white sticks) in complex with **4** (magenta sticks) (PDB ID 4IE5),²⁶ which was used as a basis for inhibitor design, with the structure of FTO Δ 31-1 (rhein, yellow sticks) (PDB ID 4IE7)²⁶ superimposed. The inset indicates how the derivatization of **4** at C6 could enable inhibition by combining fragments of 2OG and nucleobase mimetics. (B) View of the active site from a structure of FTO Δ 31 (white sticks) in complex with **13c** (cyan sticks surrounded by OMIT mF_o-DF_c electron density displayed as green mesh, contoured to 3.0σ). (C) Superimposition of a structure of FTO Δ 31-**13c** with that of FTO Δ 31-**4** (PDB ID 4IE5; **4** in magenta) and FTO Δ 31-1 (PDB ID 4IE7, **1** in yellow). (D) View of the active site of FTO in complex with **14a**. The FTO Δ 31 active site (white sticks) showing OMIT electron density (mF_o-DF_c , contoured to 3.0σ in a green mesh) around **14a** (salmon sticks). (E) View of superimposed structures of FTO Δ 31-**13c** (PDB ID 4QHO, **13c** cyan sticks), FTO Δ 31-**14a**, and a FTO-ssDNA substrate (lime green sticks) complex (PDB ID: 5ZMD). Only FTO residues (white sticks) from the FTO Δ 31-**14a** structural complex are shown. (F) Superimposed structures of FTO Δ 31-**13c** (PDB ID 4QHO, **13c** cyan sticks) and FTO Δ 31-**14a**. Residues from FTO Δ 31-**14a** are white sticks; the substrate binding Glu234 side chain from FTO Δ 31-**13c** is highlighted in purple sticks. Note: the nitro-phenyl group of **14a** displaces the substrate binding Glu234 side chain. Non-carbon atoms colored: O (red), N (blue), Zn (gray sphere), and H-bond, electrostatic and metal coordination interactions are indicated as black dashes.


naphthalene (**13c**) gave more potent inhibition (IC_{50} 4 ± 1 μ M), similar to that of FG-2216 (**2**) (IC_{50} 2.8 ± 0.9 μ M). **13c** was, however, more selective for FTO, compared to **2** and the other compounds in this series over the JmjC KDMs. Quinoline derivative **13d** was prepared as a more basic and water-soluble analogue of **13c** but manifested a 6-fold decrease in potency against FTO (**13d**, IC_{50} 25 ± 1 μ M) relative to **13c**. To investigate the binding mode of **13c**, we obtained a structure of FTO Δ 31 with Zn substituting for Fe in the complex with it (2.6 Å resolution, PDB ID 4QHO). The structure was solved by molecular replacement using an FTO-4

complex structure (PDB ID 4IE5) as a search model. There was clear electron density for **13c** in the active site revealing that the hydroxypyridinyl glycol scaffold manifests a similar binding mode as we have previously observed for **4** (PDB ID 4IE4),²⁶ with hydrogen bonding interactions occurring between the 3-hydroxy group on the pyridine ring and the Asn205 side chain and additional electrostatic and hydrogen bonding interactions, respectively, between the glycol carboxylate and the side chains of Arg316, Ser318, and Tyr295 (Figure 2B). As predicted, the **13c** 1-naphthyl side chain extends to occupy the substrate binding site (Figure 2B), with

Table 1. IC₅₀ Values of Compounds against FTO and Selected Human 2OG Oxygenases

No.		FTO (1.2 μM) ^a (100 nM)	PHD2 (150 nM)	FIH (150 nM)	KDM3A (0.25 nM)	KDM4C (2.0 nM)	KDM6B (0.1 nM)	KDM5B (2.0 nM)	KDM2A (25 nM)
13a		35.2±3.0 ^a	18.4 ^b (16.4-20.7)	n.d.	>100 ^c	>100 ^c	>100 ^c	56.6 ^c (41.8-76.5)	36.8 ^c (23.8-56.9)
13b		11.1±0.8 ^a	11.5 ^b (10.4-12.9)	n.d.	13 ^c	27 ^c	39.7 ^c	88.8 ^c (75.6-104.2)	50.2 ^c (40.4-62.4)
13c		2.3±0.5 ^a	n.d.	n.d.	>100 ^c	>100 ^c	76.4 ^c	>100 ^c	>100 ^c
13d		23.2±1.1 ^a	>100 ^b (75.0-153.6)	n.d.	>100 ^c	>100 ^c	>100 ^c	40.5 ^c (32.5-50.5)	84 ^c (67.9-104.0)
14a		0.08±0.005 ^b 1.5±0.5 ^a	2.2 ^b (2.1-2.4)	45.9 ^b (38.8-54.3)	>100 ^c (74.0-152.3)	>100 ^c (116.1-294.2)	19.6 ^c (15.8-24.2)	46.3 ^c (33.8-63.5)	>100 ^c
14b		0.33±0.05 ^b 12.2±0.8 ^a	2.6 ^b (2.4-2.7)	50.1 ^b (42.3-59.3)	41.9 ^c (24.2-72.6)	44.4 ^c (37.1-53.2)	38.4 ^c (30.6-48.4)	87.8 ^c (69.6-110.8)	>100 ^c
14c		5.1±0.6 ^b 60.2±2.7 ^a	21.3 ^b (18.8-24.1)	14.0 ^b (12.1-16.2)	52.0 ^c (40.9-66.1)	>100 ^c (77.0-131)	89.7 ^c (72.2-111.6)	63.1 ^c (48.8-82.8)	>100 ^c (68.8-296.8)
14d		0.8±0.7 ^b 6.9±0.6 ^a	n.d.	n.d.	51.3 ^c (31.1-84.6)	63.9 ^c (52.0-78.4)	>100 ^c (37.1-292.5)	39.8 ^c (14.6-108.5)	81.0 ^c (66.0-99.5)
14e		26.0±1.7 ^b	9.5 ^b (9.1-9.9)	18.4 ^b (15.1-22.3)	n.d.	n.d.	n.d.	n.d.	n.d.
14f		15.2±1.2 ^b	59.8 ^b (51.6-69.4)	>100 ^b (70.3-150.4)	n.d.	n.d.	n.d.	n.d.	n.d.
14g		0.9±0.7 ^b 5.8±0.4 ^a	6.0 ^b (5.6-6.5)	50.0 ^b (42.0-59.5)	>100 ^c	>100 ^c	89.7 ^c (21.1-381.9)	>100 ^c (43.5-287)	>100 ^c
14h		0.43±0.09 ^b 6.2±0.4 ^a	7.8 ^b (7.1-8.7)	61.9 ^b (53.7-71.4)	69.4 ^c (13.3-361.7)	>100 ^c	47.8 ^c (29.2-78.3)	17.7 ^c (11.8-26.7)	>100 ^c
14i		1.4±0.7 ^b 54.5±1.9 ^a	10.9 ^b (9.5-12.7)	40.7 ^b (29.6-56.1)	>100 ^c	>100 ^c	>100 ^c	53.4 ^c (29.5-96.8)	>100 ^c
15 ²¹		12.5±0.7 ^a	>100 ^b	n.d.	0.4 ^c (0.3-0.6)	>100 ^c	13.7 ^c (10.6-17.7)	83.9 ^c (53.8-131)	0.063 ^c (0.06-0.07)

^aIC₅₀ values (in μM) obtained from the 5-mer m⁶A RNA LCMS-based demethylation assay. ^bSPE-MS-based assay. ³⁴ ^cA histone demethylase luminescence-based AlphaScreen assay. ³⁵ For SPE-MS and AlphaScreen assays, the data represent IC₅₀ values plus lower and upper 95% confidence limits (in parentheses). Enzyme concentrations employed are stated in parentheses on the first row. The high IC₅₀ for 14c (IC₅₀ 5.1 μM) may in part be due its relative lack of solubility at the tested concentrations. Note: n.d., not determined.

Scheme 1. Synthesis of FTO inhibitors^a

^aSuzuki or Buchwald–Hartwig Pd-couplings were used to couple the C-6 position of the pyridinyl ring with different aryl rings/aryl amines. Reagents and conditions: (i) Br₂ (1.1 equiv), H₂O, 3 days; (ii) NaOH 30%, MeOH, reflux, 12 h; (iii) GlyOC(CH₃)₃ or GlyOCH₃, or GlyOCH₂Ph (1.5 equiv), propylphosphonic anhydride (1.5 equiv), diisopropylethylamine (4 equiv), mw, 4 h; (iv) RB(OH)₂ (1.3 equiv), K₂CO₃ (4 equiv), Pd(PPh₃)₄ (10 mol%), mw, 130 °C; (v) ArNH₂ (1.2 equiv), BrettPhos (0.15 equiv), BrettPhosLigand G1 (0.01 equiv), K₃PO₄ (1.2 equiv); (vi) KOH (excess), THF; (vii) Pd/C (10 mol%), THF, r.t.

the plane of its naphthyl group being near orthogonal relative to its pyridine ring. The 1-naphthyl group appears to form partial π – π interactions with the indole side chain of His231. The superimposition of the structures of FTO Δ 31 in complex with **4**, **1**, and **13c**, show a substantial overlap, in particular the naphthyl group of **13c** is positioned similar to two of the three anthraquinone rings of rhein (**1**) (Figure 2C).

Because **13c** showed enhanced potency and higher selectivity compared to reported FTO inhibitors, we used the FTO Δ 31–**13c** structure as a basis for the design of further inhibitors. Analyses of the FTO Δ 31–**13c** structure suggests that the introduction of a heteroatom between the pyridinyl ring and the C-6 aryl substituent of the original series would provide additional side chain flexibility and potentially position the aryl ring between the side chains of Tyr106 and Tyr108.

Buchwald–Hartwig coupling was thus used to prepare the aniline derivatives (**14a–i**), which were tested against FTO and 10 other 2OG oxygenases (Tables 1 and S2). We initially employed an optimized LCMS-based assay using a 5-mer m⁶A RNA oligonucleotide as the substrate and 1.2 μ M FTO (Figure S3) to investigate the IC₅₀s of **13a–d**, **14a–d**, **14g–i**, and **15** (a reported FTO inhibitor).²¹ The IC₅₀s of **14a–d** and **g–i** range from 1.5 to 60.2 μ M, with the majority displaying increased potencies over **13a–d** (2.3–35.2 μ M) (Table 1). The most potent of the tested FTO inhibitors was **14a** (IC₅₀ 1.5 μ M), which has a *p*-nitrophenyl side chain (Table 1). Against the panel of 2OG oxygenases, **14a–d** and **g–i** showed generally greater selectivity than **13a–d** toward FTO. For the majority of JmjC KDMs screened, IC₅₀ values were in the tens of μ M to >100 μ M. The selectivity of the **14a–d** and **g–i** series for FTO over PHD2 was less pronounced (IC₅₀ range 2.2–59.8 μ M) but with the most potent FTO inhibitor, **14a**, being ~30-fold more selective for FTO over PHD2 under the tested conditions.

With the LCMS-based assays, the IC₅₀ measurement of **14a** (1.5 μ M) was limited as it was near the FTO concentration (1.2 μ M). We thus developed a more sensitive hydroxylation assay employing a lower FTO concentration (100 nM) with the solid-phase extraction coupled to MS (SPE-MS) (Figure S4, Table 1). Instead of demethylation, this assay monitors the hydroxylated product (hydroxymethyladenine, hm⁶A) of a 15-mer m⁶A-containing RNA oligonucleotide (hm⁶ has been reported to be a relatively stable adduct).^{17,19} We determined the IC₅₀s of **14a–i** using SPE-MS.

The SPE-MS results show that the two compounds with *p*-nitrophenyl/*p*-nitropyridinyl groups at C-6 of the core

pyridine, that is, **14a/14b**, are the most potent of the FTO inhibitors (IC₅₀s 80 and 330 nM, respectively), followed by the *N*-methyl amide-phenyl (**14h**, IC₅₀ 430 nM), amine-pyridyl (**14d**, 800 nM), ester (**14g**, 830 nM), *N*-dimethyl amide-phenyl (**14i**, 1.4 μ M), and amine-phenyl (**14c**, IC₅₀ = 5.1 μ M) C-6 substituents. The compounds with benzoic acid **14f** and naphthylamine **14e** side chains were the weakest FTO inhibitors (IC₅₀s 15.2 and 26 μ M, respectively). Even though the C-6 nitro-pyridine analogue (**14b**) has a 4-fold higher IC₅₀ than the nitro-phenyl analogue **14a**, the amine-pyridine substituent **14d** has a lower IC₅₀ than the amine-phenyl derivative **14c**, thus pyridines at C-6 can be productively accommodated within the active site.

Changing the para-nitro group of the C-6 phenyl ring of **14a** to an amide, as in the monomethyl amide **14h** (IC₅₀ 430 nM) or dimethyl amide **14i** (IC₅₀ 1.4 μ M) increases the IC₅₀ values by ~5–18 fold over **14a**, respectively. In general, substituting the nitro group of **14a** (amine: **14c** and **14d**; amide: **14h** and **14i**; carboxylate: **14f**; and ester: **14g**) resulted in a reduction in potency.

The results of testing **13a–d**, **14a–i**, and a previously reported selective FTO inhibitor **15**,²¹ against a panel of human 2OG oxygenases (Tables 1 and S2) revealed that, except for hydrazine compound **15** (FTO IC₅₀ 12.5 \pm 0.7 μ M; LCMS-based assay), the hydroxy pyridine-glycyl compounds were for the most part selective for FTO and PHD2. Interestingly, **15** was identified as a potent inhibitor of the histone H3 lysine 36 JmjC KDM2A (IC₅₀ 63 nM), which is a potential cancer target.^{36,37}

To confirm that the compounds inhibit FTO by binding at the active site, we performed a competition-based NMR binding assay³⁸ (using 2OG as a competitor) to obtain binding constants for the selected compounds (**13c**, **14a**, **14h**, and **14i**) (Figures S5 and S6). The rankings of the *K_D* values were generally in accord with the rankings of the IC₅₀ values: **14a** (*K_D* 0.34 \pm 0.16 μ M, IC₅₀ 1.5 \pm 0.5 μ M), **13c** (*K_D* 1.2 \pm 0.24 μ M, IC₅₀ 2.3 \pm 0.5 μ M), **14h** (*K_D* 0.67 \pm 0.29 μ M, IC₅₀ 6.2 \pm 0.4 μ M), and **14i** (*K_D* 3.9 \pm 1.6 μ M, IC₅₀ 54.5 \pm 1.9 μ M).

We co-crystallized FTO Δ 31 with **14a** and determined its structure (2.6 Å resolution). The structure revealed that the hydroxypyridyl-glycine core of **14a** binds as observed for **4**, in the 2OG binding site (Figures 2D and S7). **14a** coordinates to the metal (Zn substituting for Fe) via its pyridinyl nitrogen and the carbonyl oxygen, and its glycyl carboxylate forming a salt bridge with the side chain of Arg316 and hydrogen bonds with the side chains of Ser318 and Tyr295. In the FTO Δ 31–**14a**




Figure 3. Structure-based rationalization of selectivity of FTO inhibitors. (A) View of the active site of the AlkBΔN11-14a complex (PDB ID 7NRO); **14a** (green sticks) with surrounding OMIT electron density $mF_o - DF_c$ shown as a green mesh and contoured to 3.0σ . (B) View of the FTOΔ31-14a structural complex (FTO in white sticks) (PDB ID 7E8Z) superimposed on a structure of AlkBΔN11-14a. Note: **14a** (salmon sticks, AlkB; green sticks, FTO) binds slightly differently to FTO and AlkB in particular, the metal-coordinating atoms of **14a** and the metal ion are coplanar with AlkB. (C) View of the active site from a structure of PHD2 (yellow sticks and surface) superimposed with a structure of FTOΔ31 in complex with **13c** (PDB ID 4QHO) (derived from a structure of the PHD2-2 complex PDB ID 4BQX,³⁹ ligand not shown for clarity) indicating how the naphthyl side chain of **13c** may clash with Tyr310 in the PHD2 active site, so reducing its affinity (FTOΔ31 residues are not shown for clarity). (D) View of the active sites of structures of FTOΔ31 and AlkBΔN11 in complex with **14a** (FTO, salmon sticks; AlkB, green sticks) (PDB ID 7E8Z and 7NRO) superimposed onto PHD2 (yellow sticks and surface). Note the nitrophenyl side chain of **14a** occupies the PHD2 active site opening with a potential for minor clashes, notably for AlkB **14a** binding mode (green sticks). (E) View from a structure of FTO in complex with **13c** superimposed onto a structure of KDM4C in complex with **5** (PDB ID 2XML)⁴⁰ (KDM4 C shown as light blue sticks and surface; **5** in gray sticks) showing that the side chain of **13c** may clash with Lys243 of KDM4C. (F) View from complexes of FTOΔ31-**14a** (salmon sticks) and AlkBΔN11-**14a** (green sticks) superimposed on the structural complex of KDM4C-**5** (PDB ID 2XML)⁴⁰ showing how the C-6 naphthyl side chain of **14a** may clash with Lys243 and/or Asp193 of KDM4C. Non-carbon atoms colored: O (red), N (blue), Zn (gray sphere), Mn (purple sphere), and Ni (light green); H-bond, electrostatic, and metal coordination interactions are indicated as black dashes.

complex, the **14a** carbonyl oxygen is positioned *trans* to the metal-coordinating residue Asp233 and the metal-coordinating pyridine nitrogen atom is *trans* to the metal coordinating residue His307. The plane formed by the pyridinyl ring of **14a** is skewed with respect to the plane formed by its pyridinyl nitrogen and carbonyl oxygen and the active site metal (Figure S7A,B). This orientation is unusual, especially when compared

to the more typical co-planar orientation seen in the FTOΔ31-**4** structure (Figure S7B).

To investigate the generality of the skewed binding mode of **14a** as observed with FTO, we solved a crystal structure of the related bacterial NAOX AlkBΔN11 in complex with it (Figure 3A). By contrast with the crystallographically observed FTO binding mode of **14a**, in the AlkB-**14a** structure, the plane formed by the metal-coordinating atoms of **14a** and the metal-

ion are co-planar with the pyridinyl ring (Figure 3B). Contrary to the binding mode observed with FTO, the *p*-nitrophenyl group of **14a** exits the center of the AlkB active site without significantly displacing key substrate binding side chains (Figure 3A,B). The binding mode of **14a** in AlkB is different from the previously reported potent AlkB glycinamide inhibitors where their side chains are typically positioned in a hydrophobic pocket close to Trp178, Ile143, and Phe154 (Figure S8).³¹

Pleasingly, as predicted, the amine linker of **14a** apparently enables its *p*-nitrophenyl group to have a different orientation in FTO compared to the orientation of the naphthalene of **13c** (Figure 2F). With **14a**, the nitrogen of the amine linker is positioned to potentially form a hydrogen bond with the Arg322 side chain (2.9 Å); the Arg322 side chain is also positioned to form a cation- π interaction with the pyridine ring of **14a**. The *p*-nitrophenyl group of **14a** is positioned between the Glu234 and Tyr108 side chains of FTO. Notably, the Glu234 side chain is displaced ~ 5 Å by the *p*-nitrophenyl moiety toward the surface of the protein (Figures 2F and S9), an unprecedented observation in available FTO inhibitor structures (Figure 2).^{7,20,21,23–26,41} Glu234 is important as it has also been shown to interact with m⁶A in a structure of an FTO variant in complex with a ssDNA substrate.⁴² Analysis of the FTO variant:ssDNA structural complex suggests that electrostatic repulsion between the negatively charged Glu234 side chain and the phenyl carboxylate of **14f** (IC₅₀ 15.2 μ M) may account for the large (190-fold) difference in IC₅₀ between the isomers **14a** and **14f**. Removing the inhibitor carboxylate group by substitution with a methyl ester **14g** (IC₅₀ 860 nM) appeared to partially rescue potency resulting in a 10-fold difference relative to **14a**. The structural analysis implies that bulky naphthalene of **14e** would encounter steric hindrance in the pocket where the *p*-nitrophenyl group of **14a** is situated, explaining its significant 325-fold lower potency (IC₅₀ 26 μ M).

DISCUSSION AND CONCLUSIONS

Our structure-guided approach to FTO inhibition was based on the knowledge that although Fe(II) and 2OG binding by 2OG oxygenases occurs by a conserved general process, that of substrate binding varies considerably, not least because the nature of the substrates varies for different sub-families of human 2OG oxygenases.^{12,15} Following analysis of structures of FTO in complex with a 2OG mimic (**4**) and rhein (**1**), which binds competitively with the substrate nucleobase (Figure S2), this approach resulted in compounds (e.g., **13b** and **c**) which were more potent than **4**. Following crystallographic studies of FTO with **13c**, derivatives of **4** were further optimized to highly potent FTO inhibitors such as **14a**, the proposed general binding mode of which was also validated by crystallographic analyses. The 2OG competing inhibition mode of these inhibitors was supported by NMR studies.

Importantly, although there is likely scope for further optimization using a larger set of 2OG oxygenases in counter screening, some of the compounds we developed show selectivity for FTO (Tables 1 and S2), which in some cases can be rationalized on the basis of structural information. For instance, the set of compounds with an aryl ring directly linked to C-6 of the pyridine ring of the scaffold (**13a–d**) are generally more selective for FTO over PHD2, compared to **14a–i** where the aryl ring is linked to the pyridine C-6 via an amine. The superimposition of our FTO Δ 31-**13c** structural

complex with that of PHD2-**2**³⁹ reveals that the C-6 aryl ring of **13c** will likely clash with the PHD2 Tyr310 side chain (Figure 3C), thus rationalizing in part why this set of FTO inhibitors is selective toward FTO over PHD2. In contrast, the superimposition of the FTO Δ 31-**14a** and AlkB-**14a** structures with the PHD2-**2** structure reveals that the nitrophenyl group of **14a** will likely project into an unoccupied space at the active site entrance of PHD2 (Figure 3D). The lack of steric hindrance for the C-6 aryl ring of **14a** (and by implication) when modeled in PHD2 is thus proposed to lower its selectivity toward FTO over PHD2. The superimposition of the structural complexes of FTO Δ 31-**13c**, FTO Δ 31-**14a**, and AlkB Δ N11-**14a** with KDM4C-5 as a representative of JmjC oxygenases suggests that similar steric clashes of **14a** proposed for PHD2 may also occur in the KDM4C active site (Figure 3E,F). The superimposed structures also reveal that the hydroxypyridinyl compounds adopt a similar metal-ion binding mode as **5** does with KDM4C, potentially providing a structural explanation for the selectivity of the C-6 substituted hydroxypyridine compounds for FTO over the JmjC subfamily of 2OG oxygenases.

It should, however, be noted that apparently clear crystallographically based structural explanations for the selectivity of inhibitors for particular 2OG oxygenases do not always manifest in experimental studies, as shown by the results with PHD inhibitors^{43–46} and some of our results for JmjC KDM inhibition (Tables 1 and S2). In this regard, it is important to note that, both in terms of 2OG and substrate binding by 2OG oxygenases, there is substantial evidence for conformational changes, as exemplified with PHD2, where such changes help enable a mechanism employing an ordered sequential active site binding of 2OG, substrate, and then dioxygen.^{43,44} Such conformational changes, at least in some cases, are observed on inhibitor binding, as observed with the PHDs.^{45,46} Further, with the JmjC KDMs, in some cases there is evidence for the inhibitor-induced Fe(II) movement.³⁰ In the case of FTO, our structure with **14a**, provides evidence that the side chain of Glu234, which is likely important in catalysis, is susceptible to conformational changes (Figures 2F and S8). In the case of the structural complex of **14a**, a skewed inhibitor binding mode with FTO was observed; the skewed binding was less apparent in a structure the bacterial NAOX AlkB Δ N11 in complexed with **14a**. Although further detailed work is required to define the precise binding mode of **14a** to FTO in solution (perhaps employing NMR), our observations illustrate why the crystallographic information should be used with care and highlight the importance of solution and empirical inhibition studies.

Nonetheless, the combined results illustrate how the knowledge of the 2OG cosubstrate and prime substrate binding modes as revealed by high-resolution crystallographic analyses can be combined to develop potent inhibitors of FTO, which is a human 2OG oxygenase of current therapeutic interest. Future work can now be directed toward the optimization of the compounds described here for *in vivo* studies aimed at defining how the reactions catalyzed by FTO are linked to its roles in health physiology and disease.

EXPERIMENTAL SECTION

Recombinant FTO and FTO Δ 31 Production and Purification. The production and purification of FTO and FTO Δ 31 were carried out as reported.²⁶ *Escherichia coli* BL21 (DE3) cells (or *E. coli* Rosetta (DE3) pLysS cells for FTO Δ 31-**14a**) were transformed with

the pET28a_FTO plasmid (encoding for N-terminally hexahistidine-tagged full-length human FTO without the thrombin cleavage site between the hexahistidine tag and the protein) or pET28a_FTO_FTOΔ31 (encoding for N-terminally hexahistidine-tagged human FTO with residues 2–31 deleted from the N-terminus) and were grown (37 °C; 180 rpm) to an OD₆₀₀ of 0.6–0.8. FTO production was induced by the addition of a final concentration of 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG); growth was continued at 16 °C for 16 h (FTO) or 18 °C for 8 h (FTOΔ31). The resultant cell pellets were stored at –80 °C. The cell pellets were thawed and resuspended in 20 mM Tris, pH 7.5; 500 mM NaCl; 10 mM imidazole, and 1 mg of DNaseI, 10 mM MgCl₂, and a Roche cOmplete protease inhibitor tablet (or 17.8 μg/mL phenylmethylsulfonyl fluoride for FTOΔ31-14a) then lysed by sonication on ice. The lysates were cleared by centrifugation, and the supernatant was loaded onto a 5 mL HisTrap column (Cytiva) and purified using an AKTA FPLC system. The column was treated with 20 mM Tris, pH 7.5; 500 mM NaCl; and 40 mM imidazole, then eluted with 20 mM Tris, pH 7.5; 500 mM NaCl; and 500 mM imidazole. The FTO solution was then buffer-exchanged into 25 mM Tris, pH 7.5, and concentrated to 20–40 mg/mL for storage. For crystallographic studies, the eluted FTOΔ31 from the HisTrap column was treated with EDTA (final concentration 200 mM) and incubated on ice for 30 min. The FTOΔ31 solution was desalted using a PD-10 desalting column with buffer A (25 mM Tris, pH 7.5), then further purified by a 5 mL HiTrap Heparin column (Cytiva), followed by a MonoQ column (Cytiva); both columns were equilibrated with buffer A (25 mM Tris–HCl, pH 7.5) and eluted with a gradient from 0 to 100% buffer B (25 mM Tris, pH 7.5; 1 M NaCl) for heparin chromatography and 0 to 60% buffer B for MonoQ ion exchange chromatography. The purified protein was then buffer-exchanged into buffer A and concentrated to 20 mg/mL for FTOΔ31-13c and 36 mg/mL for FTOΔ31-14a. The protein was snap frozen in liquid nitrogen and stored at –80 °C.

Purification of the FTOΔ31-14a Complex. A final concentration of 8 mg/mL of FTOΔ31 was mixed with a final concentration of 1 mM ZnSO₄ and a final concentration of 1 mM 14a in 25 mM Tris, pH 7.5, then incubated on ice for 30 min. The solution was loaded onto a Superdex 200 increase 10/300 GL column (Cytiva), pre-equilibrated with 25 mM Tris, pH 7.5, for purification using size exclusion chromatography. Relevant fractions corresponding to the FTOΔ31-14a complex were pooled and concentrated to 10 mg/mL.

AlkBΔN11 Expression and Purification for Crystallographic Studies. AlkBΔN11 was produced and purified as described.³¹ *E. coli* BL21 (DE3) cells were transformed with pET24a_AlkBΔN11 and allowed to grow at 37 °C until the OD₆₀₀ reached 0.6 at which point AlkBΔN11 production was induced with a final concentration of 0.5 mM IPTG. The cells were incubated at 18 °C, 180 rpm overnight (ca. 18 h). Cells pellets were thawed and resuspended to homogeneity in 0.1 M MES pH 5.8 containing 1 mM MgCl₂ with 1 mg of DNaseI and Roche cOmplete EDTA-free protease inhibitor cocktail. Cells were lysed by sonication on ice and the supernatant was obtained by centrifugation. The cell lysates were purified by cation exchange chromatography using a 50 mL S Sepharose column, with elution achieved by application of gradient of 0.1 M MES buffer, 1 M NaCl, pH 5.8. The eluted protein was further purified using a 300 mL Superdex 75 column (Cytiva), pre-equilibrated in 50 mM HEPES, pH 7.5.

In Vitro Demethylation/Hydroxylation Assays for FTO. LC-Based Assays Using the m³T Nucleoside. LC-based *in vitro* m³T demethylation assays were performed as reported.²⁶ For initial assays using LC with the m³T nucleoside substrate, a 50 μL of reaction mixture containing final concentrations of 3 μM FTO; 70 μM m³T nucleoside; 160 μM 2OG; 500 μM L-ascorbate; 100 μM diammonium iron(II) sulfate complex; 200 μM compound (or DMSO alone in control reactions); and 50 mM 2-(N-morpholino)ethanesulfonic acid (MES), pH 6.3, was incubated at room temperature for 1 h. Reactions were quenched with methanol (50 μL), then centrifuged to remove the precipitated protein. The supernatant was then dried using an Eppendorf Speedvac concentrator and reconstituted with (50 μL)

water. The product (thymidine) and substrate (m³T) were separated using a Waters Acquity Ultra Performance LC (UPLC) BEH C18 column (130 Å, 1.7 μm, 2.1 mm × 50 mm) with a gradient of 95% A (H₂O with 1% formic acid) to 80% B (methanol with 0.1% formic acid) over 5 min. The UV detection wavelength was set to 266 nm. Elution was performed at room temperature; thymidine = 0.95 min, m³T = 1.48 min. The peaks were identified in the positive ion mode using electrospray ionization-time-of-flight (ESI-TOF) mass spectrometry (Waters LCT Premier XE machine). UV peaks were integrated using MassLynx software (Agilent), and the percentage conversion of m³T to thymidine was used to quantify the activity of FTO in the presence of inhibitors. For IC₅₀ determinations, assays were carried out in triplicate with a range of compound concentrations (0, 10, 30, 100, and 300 μM and 1, 3, and 10 mM). IC₅₀ values were calculated from dose–response curves plotted using GraphPad Prism 5.

LCMS-Based Assay Using the RNA m⁶A 5-Mer Oligonucleotide. For assays using LC mass spectrometry (LCMS) with a 5-mer ssRNA oligonucleotide substrate [GG(m⁶A)CU] (Ella Biotech, Germany), a 25 μL of reaction mixture containing final concentrations of 1.2 μM FTO; 10 μM 5-mer ssRNA oligonucleotide [GG(m⁶A)CU]; 10 μM 2OG; 500 μM L-ascorbic acid; 10 μM diammonium iron(II) sulfate; and 25 mM Tris–HCl, pH 7.5, was incubated at room temperature for 30 min. After incubation, the reaction mixture was quenched with methanol (25 μL), then centrifuged (14,000 rpm, 10 min) in Seahorse polypropylene 96-well filter microplates with a 30 kDa molecular weight cutoff polyethersulfone membrane to remove FTO. The product [GGACU] and substrate [GG(m⁶A)CU] were separated using a Waters Acquity UPLC Oligonucleotide BEH C-18 column (130 Å, 1.7 μm, 2.1 mm × 50 mm) with a gradient of 98% buffer A to 70% buffer B over 8 min, at room temperature. 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) and triethylamine were used as an ion-pairing buffer for better separation of the 5-mer oligonucleotide substrate [GGm⁶ACU] and the demethylated product [GGACU]. Buffer A: 200mM HFIP, 8.15 mM TEA buffer, 5% methanol, buffer B: 20% buffer A + 80% methanol. Separation of oligonucleotides was monitored by UV; the detection wavelength was 265–292 nm. Retention times for [GGACU] and [GG(m⁶A)CU] were 2.5 and 3.0 min, respectively. The masses for each peak were confirmed by ESI-TOF mass spectrometry (Bruker Daltonics, microTOF). The area under for the substrate ([GG(m⁶A)CU]) and product ([GGACU]) peaks were integrated using data analysis software (Bruker) in the negative ion mode, and the percentage conversion of [GG(m⁶A)CU] to [GGACU] was used to quantify the demethylation activity of FTO in the presence of inhibitors. For IC₅₀ determinations, assays were carried out in triplicate with a range of compound concentrations (0, 10, 30, 100, and 300 μM and 1, 3, and 10 mM). IC₅₀ values were calculated from the dose–response curves plotted using GraphPad Prism 5.

Solid-Phase Extraction Mass Spectrometry-Based Assays. For assays using solid-phase extraction mass spectrometry (SPE-MS) with a 15-mer ssRNA oligonucleotide substrate [AUUGUGG(m⁶)-CUGCAGC], a 25 μL of reaction mixture was added 200 μM ascorbic acid; 1 μM 2OG; 0.5 μM (NH₄)₂Fe(SO₄)₂·6H₂O; 25 mM Tris, pH 7.5; 0.6 μM 15-mer ssRNA substrate; and 0.1 μM FTO, with a range of compound concentrations (3, 10, 30, 100, and 300 nM, 1, 3, 10, 30, and 100 μM). Reactions were incubated at 25 °C for 10 min before quenching with 10 mM MgCl₂. A RapidFire RF 365 high-throughput sampling robot (Agilent) attached to an iFunnel Agilent 6550 accurate mass quadrupole time-of-flight (Q-TOF) mass spectrometer operated in the positive ionization mode was used for sample analyses. The samples were aspirated under vacuum for 0.6 s and loaded onto a C-8 reverse phase solid-phase extraction (SPE) cartridge. The cartridge was washed with 6 mM octylammonium acetate (prepared by mixing 0.1 M of octylamine and 0.1 M of acetic acid with 100 mL diethyl ether on ice; this solution was cooled to –40 °C resulting in OAA crystals, which were collected and washed with cold cyclohexane.) in the LC–MS grade water treated with diethyl pyrocarbonate (5.5 s, 1.5 mL/min). The hydroxylated product

[AUUGUGG(hm⁶A)CUGCAGC] and the substrate [AUUGUGG-(m⁶A)CUGCAGC] were eluted from the SPE cartridge with 6 mM OAA 80/20_{v/v} acetonitrile/water into a mass spectrometer (5.5 s, 1.5 mL/min). The SPE cartridge re-equilibrated with 6 mM OAA in water (0.5 s, 1.5 mL/min). Mass spectrometer parameters: capillary voltage (4000 V), nozzle voltage (0 V), fragmentor voltage (250 V), gas temperature (280 °C), gas flow (13 L/min), nebulizer (40 psi), sheath gas temperature (350 °C), and sheath gas flow (12 L/min). Signal intensities were quantified as the total ion count and analyzed using RapidFire Integrator software (Agilent). Percentage hydroxylation was calculated by comparing the ion intensities of *m/z* peaks corresponding to [M - H]³⁺ to [M + OH]³⁺: % hydroxylation = 100 × (product)/(substrate + product). IC₅₀ values were calculated from the dose–response curves plotted using GraphPad Prism 5.

PHD2 and FIH Inhibition Assays. PHD2, FIH, and KDM inhibition assays were performed using a Rapidfire solid-phase extraction–mass spectrometry-based methods as described.³⁴ KDM inhibition assays were performed using an AlphaScreen-based assay as described.³⁵

NMR-Based Binding Studies. Apo-FTO was made by treatment with EDTA as follows: fractions containing purified FTO at a concentration of >1 mg/mL in 200 mM EDTA and 15 mM ammonium acetate (pH 7.0 to 8.0) was incubated overnight at 4 °C, then concentrated to 2 mL volume using an Amicon Ultra-4 or Amicon Ultra-15 centrifugal filtration units. Carr–Purcell–Meiboom–Gill (CPMG) displacement experiments were carried out using an AVIII 700 Bruker instrument equipped with a TCI inverse cryoprobe using 3 mm diameter MATCH NMR tubes with 160 μL of sample volume at 298 K. The PROJECT-CPMG sequence of Aguilar et al. was applied (90°_x–[τ–180°_y–τ–90°_y–τ–180°_y–τ]_n–acq)⁴⁷ using: total echo time 48 ms (τ = 2 ms, n = 6); acquisition time, 2.94 s; relaxation delay, 2 s; and number of scans 200–400.³⁸ Water suppression was achieved by presaturation. Samples containing 10 or 20 μM of apo FTO, 100 μM of Zn(II), 10 or 20 μM of 2OG, and 20–400 μM of the inhibitor buffered in 50 mM Tris-D₁₁/HCl (pH 7.5) and 0.02% NaN₃ (w/v) in 90% H₂O and 10% D₂O (v/v) were analyzed, and the 2OG displacement was measured via the reappearance of free 2OG signals.

The percentage of the 2OG displacement was calculated

$$\%2\text{OG displacement} = \frac{I_{2\text{OG}} - I_{2\text{OG}(0)}}{I_{2\text{OG}(\text{blank})} - I_{2\text{OG}(0)}} \times 100$$

where, *I*_{2OG} = integral of 2OG in the presence of both protein and inhibitor; *I*_{2OG(0)} = integral of 2OG in the presence of the protein (FTO) and absence of the inhibitor; *I*_{2OG(blank)} = integral of 2OG in the absence of both protein (FTO) and inhibitor; and the apparent *K*_D (*K*_D^{app}) of the inhibitors (13a–d, 14a–i) were calculated using reported methods.³⁸ The *K*_D of 2OG for FTO (1.32 ± 0.5 μM) was used as a reference value.

RNA Oligonucleotide Synthesis and Purification. RNA synthesis was performed using an Applied Biosystems 394 automated DNA/RNA synthesizer on the 1.0 μmole scale using a standard phosphoramidite cycle of detritylation, coupling, capping, and oxidation. Solid supports were packed into a TWIST column (Glen Research) for synthesis.

For non-modified RNA, 2'-*O*-TC-protected RNA phosphoramidite monomers were used (A-bz, C-ac, G-ib and U, Sigma-Aldrich). Monomers were dissolved at 0.1 M in anhydrous toluene/acetonitrile (1:1 v/v) immediately prior to use. Coupling, capping, and oxidation reagents were identical to those used in standard DNA synthesis except a solution of ethylthiotetrazole (ETT) (0.25 M in acetonitrile, Link Technologies) was used as a coupling reagent (activator). The coupling time for all monomers during RNA synthesis was 3 min. Stepwise coupling efficiencies were determined by the automated trityl cation conductivity measurement and in all cases were >97%. For the cleavage of the RNA from the solid support and deprotection of the bases and sugar, the solid support was exposed to dry ethylenediamine:toluene (1:1 v/v) for 6 h at room temperature,

washed with toluene (3 × 1 mL) then acetonitrile (3 × 2 mL), and dried using argon. The crude cleaved RNA was eluted with water.

For N⁶-methyladenosine RNA (5-mer and 15-mer), 2'-*O*-TBDMS RNA phosphoramidites (A-tac, C-tac, G-tac, and U, where tac = *tert*-butylphenoxyacetyl; Sigma-Aldrich) were dissolved in anhydrous acetonitrile (0.1 M) immediately prior to use. Coupling, capping, and oxidation reagents were 5-benzylthio-1*H*-tetrazole (0.3 M in acetonitrile; Link Technologies), fast deprotection Cap A (5% *tert*-butyl phenoxyacetyl acetic anhydride in tetrahydrofuran)/Cap B (16% *N*-methylimidazole in tetrahydrofuran), and iodine (0.1 M in tetrahydrofuran, pyridine, and water), respectively. The coupling time during RNA synthesis was 10 min. Stepwise coupling efficiencies were determined by automated trityl cation conductivity monitoring and in all cases were >97%.

For the cleavage of the RNA from the solid support and deprotection of the bases, the solid support was exposed to concentrated aqueous ammonia:ethanol (3:1 v/v) for 2.5 h at room temperature followed by 2 h at 55 °C in a sealed vial. Ammonia was removed in vacuo. To remove the 2'-TBDMS protecting group, the ammonia-free solution was freeze-dried and re-dissolved in a 1:1 mixture of dry DMSO (300 μL) and triethylaminetrihydrofluoride (300 μL) and heated for 2.5 h at 65 °C. After cooling down to room temperature, sodium acetate (3 M pH 5.2, 50 μL) and butanol (3 mL) were added, and the RNA was stored for 30 min at –80 °C. RNA was then pelleted by centrifugation (12,000g, 30 min, 4 °C), the supernatant discarded, and the pellet washed twice with 70% ethanol (750 μL). The pellet was then dried in vacuo and dissolved in water.

Oligonucleotides were purified using a Gilson HPLC system with an ACE C8 reversed-phase column (10 mm × 250 mm, pore size 100 Å, particle size 10 μm) with a gradient of buffer A (0.1 M TEAB, pH 7.5) to buffer B (0.1 M TEAB, pH 7.5 containing 50% v/v acetonitrile) and a flow rate of 4 mL/min. The gradient of acetonitrile in triethylammonium bicarbonate (TEAB) was increased from 0 to 50% buffer B over 30 min. Elution was monitored by ultraviolet absorption at 298 nm. After HPLC purification, the RNA was freeze-dried and then dissolved in water. Purified oligonucleotides were characterized by ESI mass spectrometry using a XEVO G2-QTOF MS instrument. Data were processed using MaxEnt and in all cases confirmed the integrity of the sequences.

Protein Crystallization. Crystals of the FTOΔ31-13c and FTOΔ31-14a complexes were grown in hanging drops at 293 K by the vapor diffusion method. For FTOΔ31-13c crystallization, 2 μL of the protein solution containing 8 mg/mL FTOΔ31 solution, 1 mM ZnSO₄, and 1 mM 13c was mixed with 1 μL of the reservoir solution containing 100 mM trisodium citrate pH 5.6, 8% PEG 3350, and 4% *tert*-butanol to create a crystallization drop. For FTOΔ31-14a crystallization, 1 μL of solution containing 8 mg/mL of the FTOΔ31-14a complex and 1 mM NADH was mixed with 1 μL of reservoir solution containing 100 mM trisodium citrate pH 5.6, 13.5% PEG 3350, 4% *tert*-butanol to create a crystallization drop. The drops were equilibrated with 200 μL of the reservoir solution. The resultant crystals were cryoprotected by soaking crystals in the reservoir solution diluted with 20% (v/v) glycerol before being flash cooled in liquid nitrogen.

Crystals of the AlkBΔN11-14a complex were grown using the sitting drop method at 293 K. The volume ratio of the protein to reservoir was 1:2. 1 μL of the protein solution containing 20 mg/mL AlkBΔN11, 2 mM MnCl₂, and 2 mM of 14a were mixed with 2 μL of the reservoir solution containing 0.1 M NaCl, 21% w/v PEG 3350, 0.1 M HEPES to create a crystallization drop. The resultant crystals were cryoprotected by soaking crystals in the reservoir solution diluted with 20% (v/v) glycerol before being flash cooled in liquid nitrogen.

X-ray Data Collection, Structure Determination, and Refinement. Data were collected at Diamond Light Source beamlines I04 or I24 equipped with a Pilatus 6M-F (FTOΔ31-13c and AlkBΔN11-14a) or Dectris EIGER2 9M (FTOΔ31-14a) detector, respectively. Data for FTOΔ31-13c were processed using HKL2000⁴⁸ and data for FTOΔ31-14a and AlkBΔN11-14a were processed by the beamlines autoprocessing pipeline using the XIA2

strategy.⁴⁹ FTO structures were solved by molecular replacement (MR) using PHASER⁵⁰ with a structure of FTOΔ31-4 as the search model (PDB ID 4IE5), followed by iterative cycles of map fitting in COOT⁵⁰ and refinement using PHENIX.⁵¹ The structure of AlkBΔN11-14a was solved by MR using PHASER and PDB ID 2FDJ as the search model. Iterative cycles of model building using COOT and refinement with PHENIX were performed until the converging R_{work} and R_{free} no longer decreased. 14a in the FTOΔ31-61 14a structure was refined with an occupancy of 0.7. Residual positive difference densities near the active site were present, likely derived from low occupancy citrate and/or glycerol from the crystallization mother liquor and cryoprotectant and could not be modeled with confidence. Data collection and refinement statistics for all structures can be found in Table S1.

Synthetic Chemistry Methods. Reagents were from Sigma-Aldrich, Alfa Aesar, Cambridge Biotech, Fischer Scientific, or Link Technology, unless otherwise stated. Anhydrous solvents used in reactions were either analytical grade, as obtained commercially (Alfa Aesar), or were freshly distilled. HPLC grade solvents were employed for work-up and chromatography. For the chromatographic purification of phosphoramidites, solvents were dried over P_2O_5 prior to use. Reactions involving moisture-sensitive reagents were carried out under an argon atmosphere; glassware was oven-dried and cooled under nitrogen before use. Reagents were used as supplied (analytical or HPLC grade) without prior purification. Anhydrous MgSO_4 was used as a drying agent. Microwave experiments were carried out using a Biotage Initiator 8 machine. Thin-layer chromatography was performed using aluminum plates coated with 60 F254 silica. Plates were visualized using UV light (254 nm), or 1% (m/v) aq KMnO_4 stain. Flash column chromatography was performed using Kieselgel 60 silica in a glass column, or on a Biotage SP4 flash column chromatography platform. Retention factors (R_f) are quoted to a precision of 0.05.

Deuterated solvents were from Sigma and Apollo Scientific Ltd. ^1H NMR and ^{13}C NMR spectra were recorded using Bruker AVIII400, AVIII500, AVIII600, and AVIII700 NMR spectrometers. Fields were locked by external referencing to the relevant residual deuterium resonance. Chemical shifts (δ) are reported in ppm; coupling constants (J) are recorded in Hz to the nearest 0.5 Hz; when peak multiplicities are reported, the following abbreviations are used: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broadened, dd = doublet of doublets, dt = doublet of triplets, and td = triplet of doublets. Spectra were recorded at room temperature unless otherwise stated.

Low-resolution mass spectra (m/z) and high-resolution mass spectra (HRMS) were recorded using an LCT Premier XE (Waters, MA, USA) or a microTOF (Bruker, MA, USA).

Melting points were recorded on a Gallenkamp Hot Stage apparatus. Purity of synthesized compounds was $\geq 95\%$ as determined by analytical reverse-phase LC/MS. IR spectra were recorded using a Bruker Tensor 27 FT-IR spectrometer as thin films. The selected characteristic peaks are reported in cm^{-1} .

General Synthetic Procedures. General Procedure A: Synthesis of Protected Glycinate Derivatives (Suzuki Coupling) (Scheme S1). To an overnight dried microwave vial were added the requisite aryl halide (8, 9; 1 equiv), K_3PO_4 (3 equiv), and the requisite boronic acid (1.2 equiv) in $\text{CH}_3\text{CN}/\text{H}_2\text{O}$ (3:1). The vial was evacuated and filled with N_2 three times. To this degassed solid mixture was added $\text{Pd}(\text{PPh}_3)_4$ (10 mol %); the vial was again evacuated and filled with N_2 three times. The vial was then subjected to microwave radiation (Biotage Initiator 8 machine, 135 °C, 3 h), pH was raised with 1 M NaOH. The mixture was diluted with ethyl acetate and washed with $3 \times \text{H}_2\text{O}$. The combined organic extracts were dried over anhydrous MgSO_4 and concentrated in vacuo. The crude mixture was chromatographed (cyclohexane/ethyl acetate 8:2 to 7:3) to provide the product.

General Procedure B: Synthesis of Protected Glycinate Derivatives (Buchwald Coupling) (Scheme S2). To an overnight-dried microwave vial were added the appropriate aryl halide (8–10; 1 equiv), K_3PO_4 (3 equiv), BrettPhos (16; 0.14 equiv), and Pd

precatalyst (17; 0.01 equiv). The vial was evacuated and filled with N_2 three times. To this degassed solid mixture were added appropriate amine (1.2 equiv) and $t\text{-BuOH}$ (2.5 mL). The vial was again evacuated and filled with N_2 three times. The vial was then subjected to microwave heating (Biotage Initiator 8 machine, 8 h, 140 °C). The solvent was removed under reduced pressure and the residue was diluted with ethyl acetate. The organic layer was washed with $3 \times \text{H}_2\text{O}$ and crystallized from CH_2Cl_2 . Yields varied from 22–86%.

General Procedure C: Benzyl Group Deprotection (Scheme S3). To a stirred solution of the appropriate compound (12c–d; 0.1 mmol) in THF (2 mL) was added Pd/C (10 mol %). The reaction mixture was evacuated and filled with N_2 three times. The reaction mixture was stirred for 24 h under a H_2 atmosphere. The suspension was filtered through celite pad; the filtrate was concentrated under reduced pressure. The oily residue was washed with methanol to afford the desired acid.

General Procedure D: tert-Butyl Group Deprotection (Scheme S4). To a stirred solution of compound (11a–d, 12a–b, 12e–i, 0.1 mmol) in THF was added excess KOH; the reaction was stirred for 2 days at room temperature. The crude product mixture was concentrated under reduced pressure, then diluted with ethyl acetate and water. The aqueous layer was acidified with 1 M HCl to pH 3. The resulting precipitate was filtered and washed with cold water (5 mL).

6-Bromo-3-hydroxypicolinonitrile (6). To a suspension of 3-hydroxypicolinonitrile (1.20 g, 10 mmol) in H_2O , Br_2 (0.6 mL, 11.5 mmol) was added portion wise over 3 days at room temperature. The mixture was washed with 10% sodium thiosulfate (50 mL). The product was crystallized from H_2O , resulting in a white solid (670 mg, 53%). mp 135 °C. R_f 0.20; IR (neat): ν/cm^{-1} 3150 (b, ArO–H), 2290 (–CN); ^1H NMR (400 MHz, CD_3CN): δ 7.37 (d, J = 9.0 Hz, 1H), 7.60 (d, J = 9.0 Hz, 1H), 11.56 (s, 1H); ^{13}C NMR (125 MHz, CD_3CN): δ 127.5 (ArC), 128.2 (ArC), 130.4 (ArC), 132.9 (ArC), 142.5 (ArC), 156.6 (CN); HRMS (ESI) m/z : calcd for $\text{C}_6\text{H}_2^{79}\text{BrN}_2\text{O}$ [$\text{M} - \text{H}$] $^-$, 196.9356; observed, 196.9350.

6-Bromo-3-hydroxypicolinic Acid (7). To a stirred suspension of 6-bromo-3-hydroxypicolinonitrile (6; 2.8 g, 14.1 mmol) in methanol (50 mL), 30% w/v NaOH (44 mL, 51.8 mmol) was added. The reaction mixture was heated at reflux for 12 h. The solvent was removed under reduced pressure and the suspension was acidified with concentrated HCl to pH 2. The resulting precipitate was filtered and washed with cold water (5 mL). Filtration afforded product (3.1 g, 100%) as white needles. mp 122–124 °C. IR (neat): ν/cm^{-1} 3100 (ArO–H), 2850 (COO–H), 1716 (HOC=O); ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 7.05–7.10 (m, 1H), 7.33–7.75 (m, 1H), 11.43 (s, 1H); ^{13}C NMR (125 MHz, $\text{DMSO}-d_6$) 131.2 (ArC), 133.7 (ArC), 135.8 (ArC), 137.9 (ArC), 143.3 (ArC), 169.1 (C=O); HRMS (ESI) m/z : calcd for $\text{C}_6\text{H}_3^{79}\text{BrNO}_3$ [$\text{M} - \text{H}$] $^-$, 215.9302; observed, 215.9298.

tert-Butyl (6-Bromo-3-hydroxypicolinoyl)glycinate (8). To a mixture of 6-bromo-3-hydroxypicolinic acid (7; 0.2 g, 0.92 mmol), diisopropylethylamine (0.5 mL, 2.75 mmol), and propylphosphonic anhydride solution (T3P, 0.70 mL, 1.2 mmol) in ethyl acetate (2 mL) was added glycine tert-butyl ester hydrochloride (0.2 g, 1.2 mmol). The reaction was heated under microwave irradiation at 120 °C for 4 h. The mixture was diluted with ethyl acetate and washed with water (3×10 mL) and concentrated in vacuo. The residue was purified by column chromatography (9:1 to 6:4 cyclohexane/ethyl acetate) to give a pale yellow solid (0.13 g, 42%). mp 105–106 °C. R_f 0.40; IR (neat): ν/cm^{-1} 3349 (NH), 1748 ($t\text{-BuOC=O}$), 1675 (NHC=O); ^1H NMR (500 MHz, CDCl_3): δ 1.44 (s, 9H), 4.04 (d, J = 5.5 Hz, 2H), 7.13 (d, J = 9.0 Hz, 1H), 7.40 (d, J = 9.0 Hz, 1H), 8.10 (br s, 1H), 11.83 (s, 1H); ^{13}C NMR (125 MHz, CDCl_3): δ 28.0 (C– $(\text{CH}_3)_3$), 41.5 (CH_2), 82.7 (C(CH_3) $_3$), 129.0 (ArC), 129.4 (ArC), 131.3 (ArC), 133.2 (ArC), 157.3 (ArC), 167.7 (C=O), 168.0 (C=O); HRMS (ESI) m/z : calcd for $\text{C}_{12}\text{H}_{15}^{79}\text{BrN}_2\text{NaO}_4$ [$\text{M} + \text{Na}$] $^+$, 353.0107; observed, 353.0095.

Benzyl-(6-bromo-3-hydroxypicolinoyl)glycinate (9). To a mixture of 6-bromo-3-hydroxypicolinic acid (7; 0.20 g, 0.92 mmol), DIPEA (0.5 mL, 2.75 mmol), and T3P (0.7 mL, 1.19 mmol) in ethyl acetate

793 (2 mL) was added glycine *tert*-butyl ester hydrochloride (0.2 g, 1.20
794 mmol). The reaction was subjected to microwave irradiation (120 °C,
795 4 h). The mixture was diluted with ethyl acetate and washed with
796 water (3 × 10 mL). The organic extracts were combined, dried over
797 MgSO₄, and then concentrated in vacuo. Chromatography (cyclo-
798 hexane/ethyl acetate 9:1 to 6:4) afforded the product (0.13 g, 42%) as
799 a pale yellow solid. mp 102–104 °C. R_f 0.45; IR (neat): ν/cm⁻¹ 3391
800 (Ar-OH), 3035 (N-H), 2949 (COO-H), 1741 (PhOC=O), 1654
801 (NHC=O); ¹H NMR (400 MHz, CDCl₃): δ 4.19 (d, J = 6.0 Hz,
802 2H), 5.17 (s, 2H), 7.15 (d, J = 9.0 Hz, 1H), 7.19 (s, 2H), 7.31 (m,
803 4H), 8.12 (br s, 1H), 11.72 (s, 1H); ¹³C NMR (101 MHz, CDCl₃): δ
804 40.9 (CH₂), 67.5 (CH₂), 128.5 (ArC), 128.7 (ArC), 128.7 (ArC),
805 129.1 (ArC), 129.5 (ArC), 131.2 (ArC), 133.5 (ArC), 135.0 (ArC),
806 157.4 (ArC), 168.0 (C=O), 168.8 (C=O); HRMS (ESI) m/z: calcd
807 for C₁₅H₁₂⁷⁹BrN₂O₄ [M - H]⁻, 362.9996; observed, 362.9981.

808 **Methyl (6-Bromo-3-hydroxypicolinoyl)glycinate (10).** To a
809 mixture of 6-bromo-3-hydroxypicolinic acid (7; 0.2 g, 0.92 mmol),
810 diisopropylethylamine (0.5 mL, 2.75 mmol), and propylphosphonic
811 anhydride solution (T3P, 0.70 mL, 1.2 mmol) in ethyl acetate (2 mL)
812 was added glycine methyl ester hydrochloride (0.3 g, 1.2 mmol). The
813 reaction mixture was heated under microwave irradiation at 120 °C
814 for 4 h. The mixture was diluted with ethyl acetate, washed with water
815 (3 × 10 mL), and concentrated in vacuo. The residue was purified by
816 column chromatography (7:3 to 5:5 cyclohexane/ethyl acetate) to
817 give **10** (114 mg, 43%) as white crystals, mp 88–89 °C. R_f 0.36; IR
818 (neat): ν/cm⁻¹ 3355 (O-H, N-H), 1749 (MeOC=O), 1651
819 (NHC=O); ¹H NMR (500 MHz, CDCl₃): δ 3.79 (s, 3H), 4.23 (d, J
820 = 6.0 Hz, 2H), 7.28 (d, J = 9.0 Hz, 1H), 8.07 (d, J = 9.0 Hz, 1H), 8.46
821 (s, 1H), 11.76 (s, 1H); ¹³C NMR (125 MHz, CDCl₃): δ 40.7 (CH₂),
822 52.5 (CH₃), 126.1 (ArC), 128.9 (ArC), 131.0 (ArC), 139.8 (ArC),
823 157.7 (ArC), 169.0 (C=O), 169.6 (C=O); HRMS (ESI) calcd for
824 C₉H₉⁷⁹BrN₂NaO₄ [M + Na]⁺, 310.9635; observed, 310.9623.

825 ***tert*-Butyl-*N*-((3-hydroxy-6-phenylpyridin-2-yl)carbonyl)-
826 glycinate (11a).** Following general procedure A; **8** (0.20 g, 0.6 mmol)
827 was reacted with phenylboronic acid (88 mg, 0.73 mmol), K₂CO₃
828 (0.25 g, 1.18 mmol) in CH₃CN/H₂O (4 mL) with Pd(PPh₃)₄ (70
829 mg, 0.06 mmol). Chromatography afforded compound **11a** (35 mg,
830 21%) as colorless oil. IR (neat): ν/cm⁻¹ 3400 (N-H), 3090 (C-H),
831 1737 (tBuOC=O), 1652 (NHC=O); ¹H NMR (400 MHz,
832 CDCl₃): δ 1.56 (s, 9H), 4.19 (d, J = 5.5 Hz, 2H), 7.45–7.40 (m,
833 2H), 7.52–7.47 (m, 2H), 7.84 (d, J = 9.0 Hz, 1H), 7.97–7.94 (m,
834 2H), 8.59 (t, J = 5.0 Hz, 1H), 11.95 (s, 1H); ¹³C NMR (101 MHz,
835 CDCl₃): δ 28.1 (C(CH₃)₃), 41.6 (CH₂), 82.6 (C(CH₃)₃), 126.0
836 (ArC), 126.3 (ArC), 127.1 (ArC), 128.6 (2ArC), 128.8 (2ArC),
837 130.3 (ArC), 138.1 (ArC), 147.7 (ArC), 156.9 (ArC), 160.9 (C=O),
838 168.2 (C=O); HRMS (ESI) m/z: calcd for C₁₈H₂₀N₂NaO₄ [M +
839 Na]⁺, 351.1321; observed, 351.1315.

840 ***tert*-Butyl-*N*-((6-(biphenyl-2-yl)-3-hydroxypyridin-2-yl)carbonyl)-
841 glycinate (11b).** Following general procedure A; **8** (0.20 g, 0.60
842 mmol) was reacted with (1,1'-biphenyl)-2-ylboronic acid (0.10 g, 0.72
843 mmol), K₂CO₃ (0.25 g, 1.18 mmol) in CH₃CN/H₂O (4 mL) with
844 Pd(PPh₃)₄ (70 mg, 0.0604 mmol). Chromatography afforded
845 compound **11b** (66 mg, 27%) as yellow oil. IR (neat): ν/cm⁻¹
846 3400 (N-H), 2978 (Ar C-H), 1743 (tBuOC=O), 1653 (NHC=
847 O); ¹H NMR (400 MHz, CDCl₃): δ 1.55 (s, 9H), 4.07 (d, J = 6.0 Hz,
848 2H), 7.22–7.12 (m, 3H), 7.38–7.26 (m, 4H), 7.49–7.46 (m, 3H),
849 7.73–7.69 (m, 1H), 8.18 (t, J = 6.0 Hz, 1H), 11.89 (s, 1H); ¹³C NMR
850 (101 MHz, CDCl₃): δ 28.1 (C(CH₃)₃), 41.5 (CH₂), 82.5 (C(CH₃)₃),
851 126.8 (ArC), 127.7 (ArC), 128.2 (ArC), 128.5 (ArC), 128.8 (ArC),
852 129.5 (ArC), 130.2 (ArC), 130.2 (ArC), 130.8 (ArC), 130.7 (ArC),
853 133.8 (ArC), 137.1 (ArC), 140.8 (ArC), 141.6 (ArC), 148.1 (ArC),
854 156.2 (ArC), 160.1 (C=O), 167.6 (ArC), 168.1 (ArC), 168.7 (C=
855 O); HRMS (ESI) m/z: calcd for C₂₄H₂₄N₂NaO₄ [M + Na]⁺,
856 427.1634; observed, 427.1628.

857 ***tert*-Butyl-*N*-((3-Hydroxy-6-(naphthalen-1-yl)pyridin-2-yl)-
858 carbonyl)glycinate (11c).** Following general procedure A; **8** (0.20
859 g, 0.60 mmol) was reacted with naphthalen-1-ylboronic acid (0.13 g,
860 0.72 mmol), K₂CO₃ (0.25 g, 1.2 mmol) in CH₃CN/H₂O (4 mL) with
861 Pd(PPh₃)₄ (70 mg, 0.06 mmol). Chromatography afforded
862 compound **11c** (61 mg, 27%) as yellow oil. IR (neat): ν/cm⁻¹

3400 (N-H), 2978 (C-H), 1740 (tBuOC=O), 1652 (NHC=O); 863
¹H NMR (400 MHz, CDCl₃): δ 1.52 (s, 9H), 4.14 (d, J = 6.0 Hz, 864
2H), 7.49 (d, J = 8.5 Hz, 1H), 7.60–7.50 (m, 4H), 7.67 (d, J = 8.5 865
Hz, 1H), 7.96–7.93 (m, 2H), 8.09–8.06 (m, 1H), 8.42 (t, J = 6.0 Hz, 866
1H), 12.03 (s, 1H); ¹³C NMR (101 MHz, CDCl₃): δ 28.0 867
(C(CH₃)₃), 41.5 (CH₂), 82.5 (C(CH₃)₃), 125.3 (ArC), 125.4 868
(ArC), 125.9 (ArC), 126.6 (ArC), 126.6 (ArC), 127.4 (ArC), 869
128.5 (ArC), 128.9 (ArC), 130.4 (ArC), 130.5 (ArC), 131.5 (ArC), 870
133.9 (ArC), 137.3 (ArC), 149.2 (ArC), 156.7 (ArC), 168.1 (C=O), 871
169.1 (C=O); HRMS (ESI) m/z: calcd for C₂₂H₂₂N₂NaO₄ [M + 872
Na]⁺, 401.1472; observed, 401.1462. 873

***tert*-Butyl-*N*-((3-Hydroxy-6-(quinolin-5-yl)pyridin-2-yl)carbonyl)-
874 glycinate (11d).** Following general procedure A; **8** (0.25 g, 0.76 875
mmol) was reacted with quinolin-5-ylboronic acid (0.16 g, 0.91 876
mmol), K₂CO₃ (0.31 g, 2.3 mmol) in CH₃CN/H₂O (4 mL) with 877
Pd(PPh₃)₄ (87 mg, 0.07 mmol). Chromatography afforded 878
compound **11d** (70 mg, 24%) as a white solid. mp 197–200 °C. 879
IR (neat): ν/cm⁻¹ 3200 (N-H), 1749 (tBuOC=O), 1646 (NHC= 880
O); ¹H NMR (400 MHz, CDCl₃): δ 1.46 (s, 9H), 4.12 (d, J = 6.0 Hz, 881
2H), 7.40 (dd, J = 8.5, 4.0 Hz, 1H), 7.52–7.56 (m, 1H), 7.64–7.68 882
(m, 2H), 7.74–7.78 (m, 1H), 8.16 (d, J = 8.5 Hz, 1H), 8.51–8.47 (m, 883
2H), 8.94–8.89 (m, 1H), 12.05 (s, 1H); ¹³C NMR (101 MHz, 884
CDCl₃): δ 28.0 (C(CH₃)₃), 41.4 (CH₂), 82.6 (C(CH₃)₃), 121.5 885
(ArC), 127.1 (ArC), 127.6 (ArC), 128.8 (ArC), 130.2 (ArC), 130.3 886
(ArC), 132.9 (ArC), 134.1 (2ArC), 137.35 (ArC), 147.9 (ArC), 887
148.5 (ArC), 150.4 (ArC), 157.0 (ArC), 168.1 (C=O), 168.9 (C= 888
O); HRMS (ESI) m/z: calcd for C₂₁H₂₂N₃O₄ [M + H]⁺, 380.1605; 889
observed, 380.1603. 890

***tert*-Butyl-*N*-((3-Hydroxy-6-phenylpyridin-2-yl)carbonyl)-
891 glycinate (13a).** **11a** (200 mg, 0.6 mmol) was reacted according to 892
general procedure D; concentration in vacuo afforded compound **13a** 893
(50 mg, 30%) as a white solid. mp 141–145 °C. IR (neat): ν/cm⁻¹ 894
3400 (O-H), 3200 (N-H), 3070 (C-H), 1708 (HOC=O), 1652 895
(NHC=O); ¹H NMR (400 MHz, DMSO-*d*₆): δ 4.07 (d, J = 6.0 Hz, 896
2H), 7.46–7.41 (m, 1H), 7.59–7.54 (m, 3H), 8.18 (d, J = 9.0 Hz, 897
1H), 8.25–8.23 (m, 2H), 9.48 (t, J = 6.0 Hz, 1H), 12.38 (s, 1H); ¹³C 898
NMR (101 MHz, DMSO-*d*₆): δ 41.2 (CH₂), 126.3 (ArC), 126.7 899
(ArC), 127.5 (ArC), 127.8 (ArC), 129.1 (ArC), 129.2 (ArC), 130.5 900
(ArC), 134.5 (ArC), 137.7 (ArC), 147.0 (ArC), 156.9 (ArC), 169.5 901
(C=O), 171.1 (C=O); HRMS (ESI) m/z: calcd for C₁₄H₁₁N₂O₄ 902
[M - H]⁻, 271.0719; observed, 271.0719. 903

***N*-((6-(Biphenyl-2-yl)-3-hydroxypyridin-2-yl)carbonyl)glycine
904 (13b).** Following general procedure D; concentration in vacuo 905
afforded compound **13b** (16 mg, 8%) as off white oil. IR (neat): ν/ 906
cm⁻¹ 3402 (N-H), 2913 (Ar C-H), 1750 (HOC=O), 1657 907
(HNC=O); ¹H NMR (400 MHz, DMSO-*d*₆): δ 4.09 (s, 2H), 7.09– 908
7.15 (m, 4H), 7.24–7.30 (m, 3H), 7.40–7.43 (m, 1H), 7.45–7.49 909
(m, 2H), 7.71 (dd, J = 6.0, 3.0 Hz, 1H); ¹³C NMR (101 MHz, 910
DMSO-*d*₆): δ 39.9 (CH₂), 125.3 (ArC), 126.4 (ArC), 127.3 (ArC), 911
127.9 (ArC), 128.2 (ArC), 128.6 (ArC), 129.2 (ArC), 129.9 (ArC), 912
130.0 (ArC), 130.2 (ArC), 131.7 (ArC), 132.4 (ArC), 138.0 (ArC), 913
140.9 (ArC), 141.8 (ArC), 149.5 (ArC), 155.9 (ArC), 169.2 (C=O), 914
171.1 (C=O); HRMS (ESI) m/z: calcd for C₂₀H₁₅N₂O₄ [M - H]⁻, 915
347.1037; observed, 347.1023. 916

***N*-((3-Hydroxy-6-(naphthalen-1-yl)pyridin-2-yl)carbonyl)glycine
917 (13c).** **11c** (200 mg, 0.6 mmol) was reacted according to general 918
procedure D; concentration in vacuo afforded compound **13c** (67 mg, 919
34%) as a white solid. mp 179–182 °C. IR (neat): ν/cm⁻¹ 3361 (O- 920
H), 3200 (N-H), 1749 (HOC=O), 1658 (NHC=O); ¹H NMR 921
(400 MHz, DMSO-*d*₆): δ 4.02 (d, J = 6.0 Hz, 2H), 7.67–7.54 (m, 922
5H), 7.80 (d, J = 8.5 Hz, 1H), 7.96–7.94 (m, 1H), 8.04 (dd, J = 8.0, 923
1.0 Hz, 2H), 9.17 (t, J = 6.0 Hz, 1H), 12.44 (s, 1H); ¹³C NMR (101 924
MHz, DMSO-*d*₆): δ 41.2 (CH₂), 121.15 (ArC), 125.6 (ArC), 125.85 925
(ArC), 126.5 (ArC), 127.1 (ArC), 127.2 (ArC), 127.95 (ArC), 128.8 926
(ArC), 129.1 (ArC), 130.8 (ArC), 131.1 (ArC), 133.8 (ArC), 137.5 927
(ArC), 149.2 (ArC), 156.7 (ArC), 169.4 (C=O), 170.9 (C=O); 928
HRMS (ESI) m/z: calcd for C₁₈H₁₃N₂O₄ [M - H]⁻, 321.0881; 929
observed, 321.0877. 930

***N*-((3-Hydroxy-6-(quinolin-5-yl)pyridin-2-yl)carbonyl)glycine
931 (13d).** Following general procedure D; concentration in vacuo 932

933 afforded compound **13d** (114 mg, 47%) as off white oil. IR (neat): ν /cm⁻¹ 3376 (N–H), 1730 (HOC=O), 1654 (NHC=O); ¹H NMR (400 MHz, DMSO-*d*₆): δ 4.00 (d, *J* = 6.0 Hz, 2H), 7.54 (dd, *J* = 8.5, 936 4.0 Hz, 1H), 7.63 (dd, *J* = 8.5, 2.0 Hz, 1H), 7.78 (dd, *J* = 7.0, 1.0 Hz, 937 1H), 7.90–7.84 (m, 2H), 8.13–8.11 (m, 1H), 8.43 (ddd, *J* = 8.5, 1.5, 938 1.0 Hz, 1H), 8.95 (dd, *J* = 4.0, 1.5 Hz, 1H), 9.20 (t, *J* = 6.0 Hz, 1H), 939 12.45 (s, 1H); ¹³C NMR (101 MHz, DMSO-*d*₆): δ 41.9 (CH₂), 122.5 940 (ArC), 126.3 (ArC), 127.5 (ArC), 128.2 (ArC), 130.1 (ArC), 130.8 941 (ArC), 131.2 (ArC), 134.3 (ArC), 137.8 (ArC), 148.0 (ArC), 148.3 942 (ArC), 151.0 (ArC), 156.9 (ArC), 169.40 (ArC), 171.0 (C=O), 943 172.6 (C=O); HRMS (ESI) *m/z*: calcd for C₁₇H₁₂N₃O₄ [M – H][–], 944 322.0833; observed, 322.0828.

945 **tert-Butyl (3-Hydroxy-6-((4-nitrophenyl)amino)picolinoyl)-**
946 **glycinate (12a)**. The desired product was prepared according to
947 general procedure B; the use of aryl derivative **8** (40 mg, 0.12 mmol)
948 and 4-nitroaniline (18 mg, 0.13 mmol) afforded **12a** (40 mg, 86%) as
949 a yellow solid. mp 196–200 °C. IR (neat): ν /cm⁻¹ 3400 (N–H),
950 3367 (ArO–H), 1741 (t-BuC=O), 1645 (NHC=O), 1502, 1319
951 (N–O); ¹H NMR (400 MHz, CDCl₃): δ 1.56 (s, 9H), 4.15 (d, *J* =
952 5.0 Hz, 2H), 6.82 (br s, 1H), 7.07 (d, *J* = 9.0 Hz, 1H), 7.36 (d, *J* = 9.0
953 Hz, 1H), 7.45 (d, *J* = 1.0 Hz, 2H), 8.18 (br s, 1H), 8.24 (d, *J* = 1.0 Hz,
954 2H), 11.60 (s, 1H); ¹³C NMR (101 MHz, CDCl₃): δ 28.1
955 (C(CH₃)₃), 41.6 (CH₂), 83.0 (C(CH₃)₃), 116.1 (ArC), 118.9
956 (ArC), 125.8 (ArC), 127.4 (ArC), 129.6 (ArC), 141.2 (ArC), 144.6
957 (ArC), 146.9 (ArC), 153.5 (ArC), 168.3 (C=O), 168.5 (C=O);
958 HRMS (ESI) *m/z*: calcd for C₁₄H₁₂N₄O₆ [M – H][–], 331.0684;
959 observed, 331.0684.

960 **tert-Butyl (3-Hydroxy-6-((5-nitropyridin-2-yl)amino)picolinoyl)-**
961 **glycinate (12b)**. The product was prepared according to general
962 procedure B; the use of aryl derivative **8** (40 mg, 0.12 mmol) and 5-
963 nitropyridin-2-amine (18 mg, 0.13 mmol) afforded **12b** (34 mg, 73%)
964 as a yellow solid. mp 196–200 °C. IR (neat): ν /cm⁻¹ 3387 (N–H),
965 3300 (ArO–H), 1742 (t-BuC=O), 1647 (NHC=O), 1504, 1382
966 (N–O); ¹H NMR (400 MHz, CDCl₃): δ 1.47 (s, 9H), 4.07 (d, *J* =
967 5.0 Hz, 2H), 7.32–7.37 (m, 2H), 7.59 (s, 1H), 7.75 (d, *J* = 9.0 Hz,
968 1H), 8.10–8.16 (m, 1H), 8.33 (s, 1H), 9.07 (t, *J* = 5.0 Hz, 1H), 11.56
969 (s, 1H); ¹³C NMR (101 MHz, CDCl₃): δ 28.1 (C(CH₃)₃), 41.6
970 (CH₂), 68.3 (C(CH₃)₃), 109.4 (ArC), 120.2 (ArC), 122.3 (ArC),
971 129.4 (ArC), 133.5 (ArC), 138.1 (ArC), 143.1 (ArC), 145.9 (ArC),
972 154.2 (ArC), 157.1 (ArC), 168.2 (C=O), 168.7 (C=O); HRMS
973 (ESI) *m/z*: calcd for C₁₇H₁₈N₆O₈ [M – H][–], 388.1262; observed,
974 388.1266.

975 **Benzyl (3-Hydroxy-6-((4-nitrophenyl)amino)picolinoyl)glycinate**
976 **(12c)**. The desired product was prepared according to general
977 procedure B; the use of aryl derivative **9** (40 mg, 0.11 mmol) and 4-
978 nitroaniline (18 mg, 0.13 mmol) afforded **12c** (35 mg, 76%) as an
979 orange solid. mp 194–196 °C. IR (neat): ν /cm⁻¹ 3340 (N–H), 3289
980 (ArO–H), 1732 (t-BuC=O), 1633 (NHC=O), 1469, 1319 (NO₂);
981 ¹H NMR (400 MHz, DMSO-*d*₆): δ 4.28 (d, *J* = 6.0 Hz, 2H), 5.20 (s,
982 2H), 7.32–7.43 (m, 5H), 7.46 (d, *J* = 9.0 Hz, 1H), 7.58 (d, *J* = 9.0
983 Hz, 1H), 7.99 (d, *J* = 1.0 Hz, 2H), 8.17 (d, *J* = 1.0 Hz, 2H), 8.75 (t, *J*
984 = 6.0 Hz, 1H), 10.99 (s, 1H), 11.99 (s, 1H); ¹³C NMR (101 MHz,
985 DMSO-*d*₆): δ 49.0 (CH₂), 66.6 (CH₂), 116.5 (ArC), 126.0 (ArC),
986 126.4 (ArC), 127.4 (ArC), 128.5 (ArC), 128.9 (ArC), 136.2 (ArC),
987 139.4 (ArC), 147.0 (ArC), 148.7 (ArC), 149.5 (ArC), 153.0 (ArC),
988 166.4 (C=O), 168.9 (C=O); HRMS (ESI) *m/z*: calcd for
989 C₂₁H₁₆N₄O₆ [M – H][–], 421.1148; observed, 421.1163.

990 **Benzyl (3-Hydroxy-6-((5-nitropyridin-2-yl)amino)picolinoyl)-**
991 **glycinate (12d)**. The desired product was prepared according to
992 general procedure B; the use of aryl derivative **9** (40 mg, 0.11 mmol)
993 and amine 5-nitropyridin-2-amine (18 mg, 0.13 mmol) afforded **12d**
994 (30 mg, 65%) as an orange solid. mp 190–195 °C. IR (neat): ν /cm⁻¹
995 3352 (N–H), 3340 (Ar–OH), 1740 (MeOC=O), 1644 (BzOC=O),
996 1605 (NHC=O), 1542, 1324 (N–O); ¹H NMR (400 MHz,
997 CDCl₃): δ 4.22 (d, *J* = 6.0 Hz, 2H), 5.21 (s, 2H), 7.25–7.43 (m, 7H),
998 7.57 (br s, 1H), 7.69–7.78 (m, 1H), 8.11 (br s, 1H), 8.33 (d, *J* = 10.0
999 Hz, 1H), 9.00–9.21 (m, 1H), 11.47 (s, 1H); ¹³C NMR (101 MHz,
1000 CDCl₃): δ 40.5 (CH₂), 67.6 (CH₂), 109.4 (ArC), 116.5 (ArC), 118.5
1001 (ArC), 120.25 (ArC), 122.8 (ArC), 129.4 (ArC), 133.5 (ArC), 138.1
1002 (ArC), 143.1 (ArC), 145.9 (ArC), 154.2 (ArC), 157.1 (ArC), 168.2

(C=O), 168.7 (C=O); HRMS (ESI) *m/z*: calcd for C₂₀H₁₆N₅O₆ 1003
[M – H][–], 422.1106; observed, 422.1110. 1004

Methyl-4-((5-hydroxy-6-((2-methoxy-2-oxoethyl)carbamoyl)-
pyridin-2-yl)amino)benzoate (12f). The desired product was 1005
prepared according to general procedure B; the use of aryl derivative 1006
10 (40 mg, 0.14 mmol) and methyl 4-aminobenzoate (26 mg, 0.17 1007
mmol) afforded **12f** (32 mg, 64%) as a yellow solid. mp 170–175 °C. 1008
¹H NMR (500 MHz, DMSO-*d*₆): δ 3.71 (s, 3H), 3.81 (s, 3H), 4.20 1009
(d, *J* = 6.0 Hz, 2H), 7.17 (d, *J* = 9.0 Hz, 1H), 7.42 (d, *J* = 9.0 Hz, 1H), 1010
7.69–7.74 (m, 2H), 7.88–7.93 (m, 2H), 8.58 (t, *J* = 6.0 Hz, 1H), 1011
9.55 (s, 1H), 11.85 (s, 1H); ¹³C NMR (126 MHz, DMSO-*d*₆): δ 41.4 1012
(CH₂), 52.1 (CH₃), 52.5 (CH₃), 113.1 (ArC), 116.5 (ArC), 120.8 1013
(ArC), 120.8 (ArC), 126.3 (ArC), 129.8 (ArC), 131.2 (ArC), 131.6 1014
(ArC), 146.5 (ArC), 147.3 (ArC), 152.5 (ArC), 166.6 (C=O), 169.6 1015
(C=O), 170.3 (C=O); HRMS (ESI) *m/z*: calcd for C₁₇H₁₈N₃O₆ 1016
[M + H]⁺, 360.1190; observed, 360.1191. 1017

Methyl-4-((6-((2-benzyloxy)-2-oxoethyl)carbamoyl)-5-hydroxy-
pyridin-2-yl)amino)benzoate (12g). The desired product was 1018
prepared according to general procedure B; the use of aryl derivative 1019
9 (40 mg, 0.11 mmol) and methyl 4-aminobenzoate (20 mg, 0.13 1020
mmol) afforded **12g** (15 mg, 32%) as a yellow solid. mp 185–189 °C. 1021
IR (neat): ν /cm⁻¹ 3408 (N–H), 3352 (Ar–OH), 1740 (MeOC=O), 1022
1690 (BzOC=O), 1651 (NHC=O); ¹H NMR (400 MHz, CDCl₃): 1023
 δ 3.83 (s, 3H), 4.14–4.25 (m, 2H), 5.19 (s, 2H), 6.59 (s, 1H) 6.97 (d, 1024
6.0 Hz, 1H), 7.20–7.35 (m, 8H), 7.88–7.97 (m, 2H), 8.13 (t, *J* = 1025
9.0 Hz, 1H), 11.33 (s, 1H); ¹³C NMR (101 MHz, CDCl₃): δ 41.0 1026
(CH₂), 51.9 (CH₃), 67.6 (CH₂), 116.5 (ArC), 118.5 (ArC), 122.8 1027
(ArC), 127.0 (ArC), 128.6 (ArC), 128.7 (ArC), 128.7 (ArC), 129.4 1028
(ArC), 131.3 (ArC), 135.0 (ArC), 145.2 (ArC), 145.6 (ArC), 152.9 1029
(ArC), 166.9 (C=O), 168.8 (C=O), 169.3 (C=O); HRMS (ESI) 1030
m/z: calcd for C₂₃H₂₁N₃O₆ [M – H][–], 434.1357; observed, 434.1359. 1031

Benzyl (3-Hydroxy-6-((4-(methylcarbamoyl)phenyl)amino)-
picolinoyl)glycinate (12h). The desired product was prepared 1032
according to general procedure B; the use of aryl derivative **9** (40 1033
mg, 0.11 mmol) and 4-amino-N-methylbenzamide (20 mg, 0.13 1034
mmol) afforded **12h** (30 mg, 64%) as a yellow solid. mp 165–167 °C. 1035
IR (neat): ν /cm⁻¹ 3402 (NH), 3300 (ArOH), 1741 (BzOC=O), 1036
1646 (HNC=O), 1602 (HNC=O); ¹H NMR (400 MHz, CDCl₃): 1037
 δ 2.95 (d, *J* = 6.0 Hz, 3H), 4.20 (d, *J* = 6.0 Hz, 2H), 5.19 (s, 2H), 1038
5.96–6.07 (m, 1H), 6.48 (s, 1H), 6.93 (d, *J* = 9.0 Hz, 1H), 7.20–7.35 1039
(m, 8H), 7.66 (d, *J* = 8.5 Hz, 2H), 8.13 (t, *J* = 6.0 Hz, 1H), 11.30 (s, 1040
1H); ¹³C NMR (101 MHz, CDCl₃): δ 41.0 (CH₂), 51.9 (CH₃), 67.6 1041
(CH₂), 116.5 (ArC), 118.5 (ArC), 122.8 (ArC), 127.0 (ArC), 128.6 1042
(ArC), 128.7 (ArC), 128.73 (ArC), 129.4 (ArC), 131.3 (ArC), 135.0 1043
(ArC), 145.2 (ArC), 145.6 (ArC), 152.9 (ArC), 166.9 (C=O), 168.8 1044
(C=O), 169.3 (C=O); HRMS (ESI) *m/z*: calcd for C₂₃H₂₁N₄O₅ 1045
[M – H][–], 433.1517; observed, 433.1523. 1046

Benzyl (3-Hydroxy-6-((4-(dimethylcarbamoyl)phenyl)amino)-
picolinoyl)glycinate (12i). The desired product was prepared 1047
according to general procedure B; the use of aryl derivative **9** (40 1048
mg, 0.11 mmol) and 4-amino-N,N-dimethylbenzamide (21 mg, 0.13 1049
mmol) afforded **12i** (32 mg, 65%) as a yellow solid. mp 201–204 °C. 1050
IR (neat): ν /cm⁻¹ 3323 (b, NH, ArOH), 1750 (BzOC=O), 1632 1051
(HNC=O), 1601 (Me₂NC=O); ¹H NMR (400 MHz, CDCl₃): δ 1052
3.02 (br s, 6H), 4.20 (d, *J* = 6.0 Hz, 2H), 5.18 (s, 2H), 6.38 (s, 1H), 1053
6.94 (d, *J* = 9.0 Hz, 1H), 7.21–7.34 (m, 8H), 7.34–7.39 (m, 2H), 1054
8.16 (t, *J* = 6.0 Hz, 1H), 11.28 (s, 1H); ¹³C NMR (101 MHz, 1055
CD₃COCD₃-*d*₆): δ 26.6 (CH₃), 40.8 (CH₂), 66.5 (CH₂), 113.0 1056
(ArC), 116.6 (ArC), 119.5 (ArC), 126.0 (ArC), 128.2 (ArC), 128.5 1057
(ArC), 128.6 (ArC), 129.0 (ArC), 129.2 (ArC), 136.1 (ArC), 143.1 1058
(ArC), 147.5 (ArC), 152.2 (ArC), 169.2 (C=O), 169.5 (C=O), 1059
170.6 (C=O); HRMS (ESI) *m/z*: calcd for C₂₄H₂₃N₄O₅ [M – H][–], 1060
447.1674; observed, 447.1675. 1061

3-Hydroxy-6-((4-nitrophenyl)amino)picolinoyl)glycine (14a). 1062
The desired product was prepared according to general procedure 1063
D; glycinate **12a** (20 mg, 0.05 mmol) afforded **14a** (10 mg, 66%) as a 1064
yellow solid. mp > 300 °C. IR(neat): ν /cm⁻¹ 3387 (NH), 3386 1065
(ArOH), 2939 (COO–H), 1728 (HOC=O), 1647 (HNC=O), 1066
1577, 1334 (N–O); ¹H NMR (400 MHz, DMSO-*d*₆): δ 4.09 (d, *J* = 1067
5.0 Hz, 2H), 7.22 (d, *J* = 9.0 Hz, 1H), 7.47 (d, *J* = 9.0 Hz, 1H), 7.81 1068
1069
1070
1071
1072

(d, $J = 1.0$ Hz, 2H), 8.18 (d, $J = 1.0$ Hz, 2H), 8.83 (br s, 1H), 9.96 (t, $J = 5.0$ Hz, 1H), 11.98 (s, 1H), 12.96 (br s, 1H); ^{13}C NMR (101 MHz, DMSO- d_6): δ 28.5 (CH₂), 112.4 (ArC), 121.5 (ArC), 128.6 (ArC), 130.3 (ArC), 133.8 (ArC), 137.5 (ArC), 144.6 (ArC), 158.2 (ArC), 169.0 (ArC), 172.7 (C=O), 178.5 (C=O); HRMS (ESI) m/z : calcd for C₁₆H₁₅N₄O₅ [M - H]⁻, 331.0684; observed, 331.0685.

3-Hydroxy-6-((5-nitropyridin-2-yl)amino)picolinoyl)glycine (14b). The desired product was prepared according to general procedure D; glycinate **12b** (20 mg, 0.05 mmol) afforded **14b** (14 mg, 78%) as a yellow solid. mp > 300 °C. IR (neat): ν/cm^{-1} 3400 (NH), 3300 (ArOH), 2856 (COO-H), 1725 (HOC=O), 1647 (HNC=O), 1577, 1334 (N-O); ^1H NMR (400 MHz, DMSO- d_6): δ 4.09 (d, $J = 6.0$ Hz, 2H), 7.53 (d, $J = 9.0$ Hz, 1H), 7.77 (d, $J = 9.0$, 1H), 7.84 (d, $J = 9.0$ Hz, 1H), 8.39 (dd, $J = 9.0$, 3.0 Hz, 1H), 8.66 (t, $J = 6.0$ Hz, 1H), 9.09 (d, $J = 3.0$ Hz, 1H), 10.66 (s, 1H), 11.98 (s, 1H); ^{13}C NMR (101 MHz, DMSO- d_6): δ 21.5 (CH₂), 110.4 (ArC), 121.9 (ArC), 127.5 (ArC), 129.5 (ArC), 133.8 (ArC), 137.5 (ArC), 144.6 (ArC), 146.0 (ArC), 153.8 (ArC), 158.2 (ArC), 171.0 (C=O), 172.4 (C=O); HRMS (ESI) m/z : calcd for C₁₃H₁₀N₅O₆ [M - H]⁻, 332.0636; observed, 332.0636.

6-((4-Aminophenyl)amino)-3-hydroxypicolinoyl)glycine (14c). The desired product was prepared according to general procedure C; glycinate **12c** (20 mg, 0.05 mmol) afforded **14c** (6 mg, 43%) as a violet solid. mp > 300 °C. IR (neat): ν/cm^{-1} 3298 (b, N-H, ArO-H), 2952 (COO-H), 1720 (HOC=O), 1630 (HNC=O); ^1H NMR (400 MHz, DMSO- d_6): δ 4.22–4.29 (m, 2H), 5.21 (br s, 2H), 7.30–7.46 (m, 6H), 7.66 (br s, 1H), 8.18 (t, $J = 6.0$ Hz, 1H), 11.70 (br s, 1H); ^{13}C NMR (101 MHz, DMSO- d_6): δ 49.0 (CH₂), 116.5 (ArC), 126.0 (ArC), 126.4 (ArC), 128.5 (ArC), 128.6 (ArC), 128.9 (ArC), 129.7 (ArC), 136.2 (ArC), 139.4 (ArC), 153.0 (ArC), 166.4 (C=O), 169.8 (C=O); HRMS (ESI) m/z : calcd for C₁₆H₁₄N₃O₆ [M - H]⁻, 302.1015; observed, 302.1008.

6-((5-Aminopyridin-2-yl)amino)-3-hydroxypicolinoyl)glycine (14d). The desired product was prepared according to general procedure C; glycinate **12d** (20 mg, 0.047 mmol) afforded **14d** (3 mg, 21%) as a violet solid. mp > 300 °C. IR (neat): ν/cm^{-1} 3250 (b, N-H, ArO-H), 3000 (COO-H), 1721 (HOC=O), 1680 (HNC=O); ^1H NMR (400 MHz, DMSO- d_6): δ 4.16 (d, $J = 6.0$ Hz, 2H), 7.47 (d, $J = 9.0$ Hz, 1H), 7.56–7.62 (m, 1H), 7.84–7.89 (m, 2H), 8.14–8.17 (m, 2H), 8.51 (t, $J = 6.0$ Hz, 1H), 8.98 (s, 1H), 9.14 (s, 1H), 11.49 (br s, 1H), 11.67 (s, 1H); ^{13}C NMR (101 MHz, DMSO- d_6): δ 41.6 (CH₂), 109.4 (ArC), 120.2 (ArC), 126.3 (ArC), 128.7 (ArC), 129.6 (ArC), 136.2 (ArC), 143.1 (ArC), 145.9 (ArC), 154.2 (ArC), 157.08 (ArC), 165.8 (C=O), 170.2 (C=O); HRMS (ESI) m/z : calcd for C₁₄H₁₃N₄O₄ [M - H]⁻, 301.0942; observed, 301.0942.

(3-Hydroxy-6-(naphthalen-2-ylamino)picolinoyl)glycine (14e). The desired product was prepared according to general procedure B; glycinate **8** (40 mg, 0.12 mmol) was reacted with 2-naphthylamine (19 mg, 0.13 mmol) and the crude was reacted according to general procedure D to give **14e** (10 mg, 25%). ^1H NMR (500 MHz, DMSO- d_6): δ 4.05 (d, $J = 5.7$ Hz, 2H), 7.27 (d, $J = 9.0$ Hz, 1H), 7.37 (d, $J = 9.0$ Hz, 1H), 7.47 (t, $J = 8.0$ Hz, 1H), 7.51–7.56 (m, 2H), 7.59 (d, $J = 12.5$ Hz, 1H), 7.89–7.93 (m, 1H), 7.98 (dd, $J = 7.5$, 1.0 Hz, 1H), 8.24–8.28 (m, 1H), 8.44 (t, $J = 6.0$ Hz, 1H), 8.85 (s, 1H), 11.67 (s, 1H); ^{13}C NMR (126 MHz, DMSO- d_6): δ 41.2 (CH₂), 116.1 (ArC), 119.7 (ArC), 122.4 (ArC), 122.8 (ArC), 125.7 (ArC), 126.3 (ArC), 129.7 (ArC), 126.8 (ArC), 128.7 (ArC), 129.5 (ArC), 134.6 (ArC), 130.5 (ArC), 137.2 (ArC), 151.7 (ArC), 169.4 (C=O), 171.1 (C=O); HRMS (ESI) m/z : calcd for C₁₈H₁₆N₃O₄ [M + H]⁺, 338.1135; observed, 338.1135.

4-((6-((Carboxymethyl)carbamoyl)-5-hydroxypyridin-2-yl)amino)benzoic Acid (14f). To a solution of the methyl ester (**12f**, 359 mg, 1 mmol) in 1,4-dioxane (5 mL), 1 M lithium hydroxide (50 mg, 2 mmol) was added. The mixture was stirred at room temperature for 24 h until consumption of the starting material and then acidified with acetic acid to pH 3 and diluted with CH₂Cl₂. The solution was washed with water, dried over MgSO₄, and concentrated in vacuo to afford **14f** (100 mg, 30%) as a white solid. mp > 300 °C. ^1H NMR (500 MHz, DMSO- d_6): δ 4.10 (d, $J = 5.5$ Hz, 2H), 7.32 (d, $J = 9.0$ Hz, 1H), 7.39 (d, $J = 9.0$ Hz, 1H), 7.77 (d, $J = 9.0$ Hz, 2H),

7.87 (d, $J = 9.0$ Hz, 2H), 8.50 (t, $J = 6.0$ Hz, 1H), 9.95 (s, 1H), 11.84 (s, 1H); ^{13}C NMR (151 MHz, DMSO- d_6): δ 41.5 (CH₂), 113.0 (ArC), 116.5 (ArC), 120.6 (ArC), 122.0 (ArC), 126.2 (ArC), 129.6 (ArC), 131.2 (ArC), 131.6 (ArC), 146.3 (ArC), 147.6 (ArC), 152.2 (ArC), 167.7 (C=O), 169.3 (C=O), 171.2 (C=O); HRMS (ESI) m/z : calcd for C₁₅H₁₂N₃O₆ [M - H]⁻, 330.0732; observed, 330.0729.

3-Hydroxy-6-((4-(methoxycarbonyl)phenyl)amino)picolinoyl)glycine (14g). The desired product was prepared according to general procedure C; glycinate **12g** (20 mg, 0.05 mmol) afforded **14g** (13 mg, 82%) as a white solid. mp 264–267 °C. IR (neat): ν/cm^{-1} 3400 (NH), 3370 (ArOH), 2930 (COO-H), 1710 (MeOC=O), 1682 (HOC=O), 1592 (HNC=O); ^1H NMR (400 MHz, DMSO- d_6): δ 3.81 (s, 3H), 4.09 (d, $J = 5.5$ Hz, 2H), 7.16 (d, $J = 9.0$ Hz, 1H), 7.41 (d, $J = 9.0$ Hz, 1H), 7.73 (d, $J = 1.0$ Hz, 2H), 7.91 (d, $J = 1.0$ Hz, 2H), 8.49 (t, $J = 5.5$ Hz, 1H), 9.55 (s, 1H), 11.87 (br s, 1H); ^{13}C NMR (101 MHz, DMSO- d_6): δ 49.1 (CH₂), 52.0 (CH₃), 116.5 (ArC), 120.5 (ArC), 120.9 (ArC), 126.4 (ArC), 129.8 (ArC), 131.1 (ArC), 146.5 (ArC), 147.2 (ArC), 152.3 (ArC), 166.5 (C=O), 169.2 (C=O), 171.2 (C=O); HRMS (ESI) m/z : calcd for C₁₆H₁₄N₃O₆ [M - H]⁻, 344.0888; observed, 344.0888.

3-Hydroxy-6-((4-(methylcarbamoyl)phenyl)amino)picolinoyl)glycine (14h). The desired product was prepared according to general procedure C; glycinate **12h** (30 mg, 0.07 mmol) afforded **14h** (12 mg, 51%) as a yellow solid. mp > 300 °C. IR (neat): ν/cm^{-1} 3402 (NH), 3330 (ArOH), 2946 (COO-H), 1728 (HOC=O), 1645 (HNC=O), 1602 (HNC=O); ^1H NMR (400 MHz, DMSO- d_6): δ 2.77 (d, $J = 4.5$ Hz, 3H), 4.08 (d, $J = 5.5$ Hz, 2H), 7.13 (d, $J = 9.0$ Hz, 1H), 7.39 (d, $J = 9.0$ Hz, 1H), 7.65 (d, $J = 1.0$ Hz, 2H), 7.80 (d, $J = 1.0$ Hz, 2H), 8.18–8.21 (m, 2H), 8.52 (t, $J = 5.5$ Hz, 1H), 9.31 (s, 1H), 11.82 (s, 1H); ^{13}C NMR (101 MHz, DMSO- d_6): δ 26.6 (CH₃), 49.1 (CH₂), 116.4 (ArC), 120.2 (ArC), 126.3 (ArC), 128.7 (ArC), 129.6 (ArC), 144.6 (ArC), 147.6 (ArC), 152.0 (ArC), 166.8 (ArC), 169.4 (ArC), 171.1 (C=O), 180.0 (C=O), 208.8 (C=O); HRMS (ESI) m/z : calcd for C₁₆H₁₅N₄O₅ [M - H]⁻, 343.1048; observed, 343.1048.

6-((4-(Dimethylcarbamoyl)phenyl)amino)-3-hydroxypicolinoyl)glycine (14i). The desired product was prepared according to general procedure C; glycinate **12i** (12 mg, 0.03 mmol) afforded **14i** (3 mg, 30%) as a white solid. mp > 300 °C. IR (neat): ν/cm^{-1} 3449 (NH), 3387 (ArOH), 2863 (COO-H), 1730 (HOC=O), 1647 (HNC=O), 1592 (HNC=O); ^1H NMR (400 MHz, DMSO- d_6): δ 2.98 (s, 6H), 4.02 (d, $J = 5.5$ Hz, 2H), 7.12 (d, $J = 9.0$ Hz, 1H), 7.37 (d, $J = 8.0$ Hz, 3H), 7.66 (d, $J = 9.0$ Hz, 2H), 8.50 (t, $J = 5.5$ Hz, 1H), 9.27 (s, 1H), 11.82 (br s, 1H); ^{13}C NMR (101 MHz, DMSO- d_6): δ 21.5 (CH₃), 49.1 (CH₂), 116.6 (ArC), 112.0 (ArC), 126.3 (ArC), 127.9 (ArC), 129.0 (ArC), 129.6 (ArC), 143.2 (ArC), 147.7 (ArC), 151.8 (ArC), 169.2 (C=O), 170.7 (C=O), 171.0 (C=O); HRMS (ESI) m/z : calcd for C₁₄H₁₂N₄O₆ [M - H]⁻, 357.1204; observed, 357.1205.

(E)-4-(2-(4-Benzylnicotinoyl)hydrazineyl)-4-oxobut-2-enoic Acid (15).²¹ Compound **15** was synthesized as reported.²¹ ^1H NMR (600 MHz, DMSO- d_6): δ 4.21 (s, 2H), 6.69 (d, $J = 15.5$ Hz, 1H), 7.09 (d, $J = 15.5$ Hz, 1H), 7.55–7.16 (m, 7H), 8.63 (d, $J = 37.3$ Hz, 1H), 10.91 (s, 1H), 10.96 (s, 1H); ^{13}C NMR (151 MHz, DMSO- d_6): δ 37.2 (CH₂), 126.6 (CH), 128.6 (2ArC, CH), 129.2 (2ArC), 131.4 (2ArC), 134.2 (ArC), 138.9 (ArC), 146.3 (ArC), 151.2 (ArC), 162.3 (C=O), 166.1 (2C=O); HRMS (ESI) m/z : calcd for C₁₇H₁₆N₃O₄ [M - H]⁻, 326.1141; observed, 326.1135.

Synthesis of Phosphoramidite Protected N⁶-Methyladenosine (Scheme S5). 3',5'-O-(Di-tert-butylsilyl)-2'-O-dimethyl(tert-butyl)silylinosine (**20**).⁵² The desired compound was prepared according to a modified version of the reported procedure.⁵² To a stirred suspension of inosine (2.12 g, 8 mmol) in 40 mL of anhydrous DMF at 0 °C, di-tert-butylsilyldifluoromethanesulfonate (3.0 mL, 8.8 mmol) was added dropwise under an N₂ atmosphere. After consumption of the starting material (30 min, as assessed by TLC), the reaction was quenched immediately with imidazole (2.7 g, 40 mmol) at 0 °C. After 5 min, the reaction was warmed to room temperature. tert-Butyldimethylsilyl chloride (1.5 g, 9.6 mmol) was then added portionwise, and the reaction mixture was refluxed at 60 °C for 12 h. The suspension was then cooled to room temperature,

water was added, and the precipitate was collected by suction filtration. The filtrate was discarded, and the white precipitate was washed with cold methanol. The methanol layer was evaporated under reduced pressure and the product was crystallized from CH₂Cl₂ to give a white solid (4.0 g, 98%). m.p 191–193.4 °C. R_f 0.45 (3:2 cyclohexane/ethyl acetate); ¹H NMR (600 MHz, CDCl₃): δ 0.17 (s, 3H), 0.18 (s, 3H), 0.96 (s, 9H), 1.07 (s, 9H), 1.10 (s, 9H), 4.02–4.09 (m, 1H), 4.25 (td, J = 10.0, 5.0 Hz, 1H), 4.38 (dd, J = 9.5, 4.5 Hz, 1H), 4.45–4.58 (m, 2H), 5.96 (s, 1H), 7.87 (s, 1H), 8.11 (s, 1H), 12.56 (s, 1H); ¹³C NMR (151 MHz, CDCl₃): δ –5.0, –4.3, 18.3, 20.4, 22.8, 25.9, 27.0, 27.5, 67.8, 74.8, 75.89, 75.94, 92.3, 125.5, 138.3, 144.7, 148.1, 158.9; HRMS (ESI) *m/z*: calcd for C₂₄H₄₃O₄N₅²⁸Si₂ [M + H]⁺, 523.2767; observed, 523.2756.

3',5'-O-Bis(tert-butyl)silyl-2'-O-(tert-butyl)dimethylsilyl-N⁶-methyladenosine (21). The desired compound was prepared according to a modified version of the reported procedure.⁵² To a stirred solution of 3',5'-O-bis(tert-butyl)silyl-2'-O-(tert-butyl)dimethylsilyl inosine (20; 663 mg, 1.2 mmol) and BOP (0.64 g, 1.44 mmol) in 20 mL of THF, DBU (0.3 mL, 1.8 mmol) was added dropwise and the mixture was heated at 40 °C. After the consumption of the starting material (40 min, as assessed by TLC), the reaction mixture was cooled to room temperature and methylamine (0.3 mL, 6.0 mmol) was added dropwise and the reaction mixture was stirred overnight. The crude product mixture was concentrated under reduced pressure and diluted with ethyl acetate and was washed with water (3 × 10 mL). The organic layer was dried (anhydrous MgSO₄) and concentrated under vacuum. The residue was purified by column chromatography (9:1 to 3:2 cyclohexane/ethyl acetate) which resulted in oil (665 mg, 98%). R_f 0.20 (7:3 cyclohexane/ethyl acetate); ¹H NMR (400 MHz, CDCl₃): δ 0.00 (s, 3H), 0.02 (s, 3H), 0.78 (s, 9H), 0.90 (s, 9H), 0.94 (s, 9H), 3.05 (d, J = 1.0 Hz, 3H), 3.86–3.90 (m, 1H), 4.02–4.10 (m, 1H), 4.34 (dd, J = 9.0, 5.0 Hz, 1H), 4.38–4.44 (m, 1H), 4.47 (d, J = 4.5 Hz, 1H), 5.76 (br s, 2H), 7.62 (s, 1H), 8.22 (s, 1H); ¹³C NMR (101 MHz, CDCl₃): δ –5.0, –4.3, 18.3, 20.4, 22.8, 25.9, 27.1, 27.5, 27.6, 67.9, 74.6, 75.5, 75.8, 92.4, 120.5, 124.8, 125.0, 138.0, 153.4, 155.5; HRMS (ESI) *m/z*: calcd for C₂₅H₄₆O₄N₅²⁸Si₂ [M + H]⁺, 536.3082; observed, 536.3078. Analytical data are consistent with those reported.⁵²

2'-O-(tert-Butyl)dimethylsilyl-N⁶-methyladenosine (22). The desired compound was prepared according to the reported procedure.⁵² To a stirred solution of 3',5'-O-bis(tert-butyl)silyl-2'-O-(tert-butyl)dimethylsilyl-N⁶-methyladenosine (21; 240 mg, 0.45 mmol) in 4 mL of CH₂Cl₂ at –15 °C, a cooled solution of (HF)_x·pyridine (0.06 mL, 2.3 mmol) in 365 μL of pyridine was added. The reaction temperature was maintained at 0 °C and stirred for 12 h. The reaction was diluted with CH₂Cl₂, then washed first with sat. aq. NaHCO₃ solution and with water (3 × 10 mL). The organic layer was dried (anhydrous MgSO₄) and concentrated under reduced pressure. The residue was purified by column chromatography (9:1 to 3:2 cyclohexane/ethyl acetate) which resulted in oil (160 mg, 90%). R_f 0.15 (2:3 hexane/ethyl acetate); ¹H NMR (400 MHz, CDCl₃): δ 0.00 (s, 3H), 0.02 (s, 3H), 0.94 (s, 9H), 3.42 (d, J = 1.0 Hz, 3H), 3.89 (dd, J = 10.5, 9.0 Hz, 1H), 4.01–4.11 (m, 1H), 4.34 (dd, J = 9.0, 5.0 Hz, 1H), 4.41 (dd, J = 9.0, 5.0 Hz, 1H), 4.47 (d, J = 5.0 Hz, 1H), 5.76 (s, 2H), 7.62 (s, 1H), 8.22 (s, 1H); ¹³C NMR (101 MHz, CDCl₃): δ –5.4, –5.3, 17.9, 25.6, 25.8, 27.5, 63.5, 73.1, 74.4, 87.8, 91.3, 119.7, 140.0, 140.1, 152.9, 155.8; HRMS (ESI) *m/z*: calcd for C₁₇H₃₀O₄N₅²⁸Si [M + H]⁺, 396.2062; observed, 396.2068. Analytical data are consistent with those reported.⁵²

5'-O-(4,4'-Dimethoxytrityl)-2'-O-dimethyl(tert-butyl)silyl-N⁶-methyladenosine (23). The desired compound was prepared according to the reported procedure.⁵² To a stirred solution of 2'-O-dimethyl(tert-butyl)silyl-N⁶-methyladenosine (22; 2.6 g, 6.6 mmol) in 4 mL of anhydrous pyridine at 0 °C, DMTrCl (2.7 g, 8.0 mmol) was added portionwise at regular intervals for 12 h. The reaction was quenched by the addition of an excess of anhydrous methanol (0.5 mL) at room temperature. After 1 h, the solution was concentrated under vacuum. The crude solid was first dissolved and fractionated between aqueous NaHCO₃ and ethyl acetate; the organic layer was then washed with water (3 × 10 mL). The organic layer was dried

(MgSO₄) and concentrated under vacuum. The residue was purified by column chromatography (9:1 to 3:2 cyclohexane/ethyl acetate) resulting in green oil (3.9 g, 85%). R_f 0.45 (2:3 cyclohexane/ethyl acetate); ¹H NMR (400 MHz, CDCl₃): δ –0.13 (s, 3H), 0.00 (s, 3H), 0.86 (s, 9H), 2.77 (d, J = 4.0 Hz, 1H), 3.17 (s, 3H), 3.36–3.43 (m, 1H), 3.54 (dd, J = 10.5, 3.5 Hz, 1H), 3.80 (s, 6H), 4.27 (d, J = 3.5 Hz, 1H), 4.33–4.37 (m, 1H), 5.02 (t, J = 5.5 Hz, 1H), 5.85 (d, J = 4.5 Hz, 1H), 6.04 (br s, 2H), 6.83 (d, J = 9.0 Hz, 4H), 7.18–7.28 (m, 3H), 7.36 (d, J = 8.0 Hz, 4H), 7.47 (dd, J = 8.5 Hz, 1.5, 2H), 7.98 (s, 1H), 8.35 (s, 1H); ¹³C NMR (101 MHz, CDCl₃): δ –5.6, –5.5, 18.3, 25.8, 25.9, 55.2, 60.4, 63.0, 73.6, 75.5, 85.0, 87.5, 89.2, 113.4, 120.0, 127.3, 128.1, 128.3, 130.39, 130.45, 135.9, 138.0, 145.0, 153.0, 155.4, 158.89, 158.91; HRMS (ESI) *m/z*: calcd for C₃₈H₄₈O₆N₅²⁸Si [M + H]⁺, 698.3368; observed, 698.3359. Analytical data are consistent with those reported.⁵²

5'-O-(4,4'-Dimethoxytrityl)-(3'-O-[(2cyanoethyl)(N,N-diisopropylamino)phosphino]-2'-O-dimethyl(tert-butyl)silyl-N⁶-methyladenosine (24). The desired compound was prepared according to the reported procedure.⁵² To a stirred solution of 5'-O-(4,4'-dimethoxytrityl)-2'-O-dimethyl(tert-butyl)silyl-N⁶-methyladenosine (23, 500 mg, 0.7 mmol) in anhydrous CH₂Cl₂ in an over-dried flask under argon, DIPEA (1.3 mL, 7.2 mmol) was added dropwise and the reaction mixture was allowed to stir at 0 °C for 10 min. (2-Cyanoethyl)-N,N-diisopropylchlorophosphoramidite (0.40 mL, 1.8 mmol) was added to the reaction mixture dropwise at 0 °C under an argon atmosphere. The reaction was stirred at 0 °C for 30 min, then gradually (about 30 min) warmed to room temperature. After another 5 h under an inert atmosphere, the reaction mixture was treated with a saturated aq. KCl solution, then evaporated by rotary evaporation. The desired product was separated by silica gel column chromatography (1:1:0.01 hexane/ethyl acetate/pyridine) resulting in colorless oil (520 mg, 80%) yield. R_f 0.40 (1:1:0.01 hexane/ethyl acetate/pyridine); ¹H NMR (700 MHz, CD₂Cl₂) Major peaks are listed. δ –0.15 (s, 3H), –0.01 (s, 3H), 0.82 (s, 9H), 1.10 (s, 3H), 1.11 (s, 3H), 1.22 (s, 3H), 1.22 (s, 3H), 1.65 (s, 2H), 2.62–2.74 (m, 2H), 3.19 (s, 3H), 3.36 (dd, J = 10.5, 4.5 Hz, 1H), 3.54 (dd, J = 10.5, 4.0 Hz, 1H), 3.82 (s, 6H), 3.85–3.93 (m, 1H), 3.95–4.10 (m, 1H), 4.41–4.49 (m, 1H), 5.12 (dd, J = 6.1, 4.4 Hz, 1H), 5.33–5.40 (m, 2H), 5.79 (s, 1H), 5.99 (d, J = 6.0 Hz, 1H), 6.78–6.90 (m, 4H), 7.23–7.29 (m, 1H), 7.28–7.34 (m, 2H), 7.34–7.40 (m, 4H), 7.47–7.52 (m, 2H), 7.94 (s, 1H), 8.25 (s, 1H); ¹³C NMR (176 MHz, CD₂Cl₂) major peaks are listed. δ –5.4, –5.0, 0.8, 17.8, 20.4, 20.44, 21.1, 24.37, 24.4, 25.4, 25.44, 42.9, 43.0, 55.2, 58.8, 58.9, 63.5, 72.8, 72.9, 74.7, 74.7, 83.46, 83.48, 86.5, 88.4, 113.1, 117.8, 125.2, 126.8, 127.8, 128.1, 128.2, 129.0, 130.10, 130.14, 135.7, 139.0, 144.9, 153.0, 155.5, 158.6, 158.7; ³¹P NMR (202 MHz, CD₂Cl₂): δ 148.0, 150.8.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c01204>.

Protein crystallography data collection and refinement statistics, supplementary IC₅₀ table, IC₅₀ curves, reported FTO inhibitors, view of the active site, titration curves, superimposition of the reported AlkB inhibitor binding modes, synthesis of protected glycinate derivatives, tert-butyl group deprotection, benzyl group deprotection, and phosphoramidite protected N⁶-methyladenosine, HPLC chromatograms of the selected compounds, and supplementary references (PDF)
Molecular formula strings of compounds (CSV)

Accession Codes

PDB ID Codes: Atomic coordinates and structure factors of the crystal structures of FTO-13c (PDB ID 4QHO), FTO-14a (PDB ID 7E8Z), and AlkB-14a (PDB ID 7NRO) have been deposited in the RCSB Protein Data Bank. Authors will release the atomic coordinates upon publication.

AUTHOR INFORMATION

Corresponding Authors

Wei Shen Aik – Department of Chemistry, Hong Kong Baptist University, Kowloon Tong 99977 Hong Kong SAR, China; Email: aikweishen@hkbu.edu.hk

Michael A. McDonough – The Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford OX1 3TA, U.K.; orcid.org/0000-0003-4664-6942; Email: michael.mcdonough@chem.ox.ac.uk

Christopher J. Schofield – The Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford OX1 3TA, U.K.; orcid.org/0000-0002-0290-6565; Email: christopher.schofield@chem.ox.ac.uk

Authors

Shifali Shishodia – The Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford OX1 3TA, U.K.; Present Address: Department of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United States

Marina Demetriades – The Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford OX1 3TA, U.K.

Dong Zhang – The Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford OX1 3TA, U.K.

Nok Yin Tam – Department of Chemistry, Hong Kong Baptist University, Kowloon Tong 99977 Hong Kong SAR, China

Pratheesh Maheswaran – The Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford OX1 3TA, U.K.

Caitlin Clunie-O'Connor – The Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford OX1 3TA, U.K.

Anthony Tumber – The Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford OX1 3TA, U.K.

Ivanhoe K. H. Leung – The Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford OX1 3TA, U.K.; Present Address: School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, VIC 3010, Australia.; orcid.org/0000-0003-0633-6771

Yi Min Ng – Department of Chemistry, Hong Kong Baptist University, Kowloon Tong 99977 Hong Kong SAR, China

Thomas M. Leissing – The Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford OX1 3TA, U.K.

Afaf H. El-Sagheer – The Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford OX1 3TA, U.K.; Chemistry Branch Department of Science and

Mathematics, Suez University, Suez 43721, Egypt;

orcid.org/0000-0001-8706-1292

Eidarus Salah – The Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford OX1 3TA, U.K.

Tom Brown – The Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford OX1 3TA, U.K.; orcid.org/0000-0002-6538-3036

Complete contact information is available at:

<https://pubs.acs.org/10.1021/acs.jmedchem.1c01204>

Author Contributions

S.S., M.D., D.Z., and C.C.O. synthesized the compounds; A.H.E.-S. and T.B. synthesized the 15-mer RNA; D.Z. and E.S. produced protein; M.D., D.Z., and A.T. optimized and performed the biochemical assays; N.Y.T., P.M., Y.M.N., T.M.L., W.S.A., and M.A.M. performed protein crystallography; S.S., I.K.H.L. performed NMR-based binding assay; C.J.S., M.A.M., and W.S.A. supervised the research and analyzed the data; C.J.S., M.A.M., W.S.A., and S.S. wrote the manuscript.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

W.S.A. thanks the Research Grants Council of Hong Kong for the Early Career Scheme 2019/20 (ref. no. 22301719) for funding. C.J.S. thanks the Biotechnology and Biological Research Council, the Wellcome Trust, and Cancer Research UK for funding. This research was funded in whole, or in part, by the Wellcome Trust [grant no. 106244/Z/14/Z]. S.S. is funded by the Felix Scholarship. S.S. thanks Dr. Adam Hardy, University of Oxford, for useful scientific discussion. We thank the Diamond Light Source and staff for the allocation of beam time and support. For the purpose of open access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.

ABBREVIATIONS

ALKBH, AlkB homologue; CPMG, Carr–Purcell–Meiboom–Gill; DIPEA, diisopropylethylamine; DMSO, dimethylsulfoxide; ESI, electrospray ionization; ETT, ethylthiotetrazole; FIH, factor inhibiting hypoxia-inducible factor; FTO, fat mass- and obesity-associated protein; HFIP, 1,1,1,3,3,3-hexafluoro-2-propanol; HRMS, high-resolution mass spectra; IPTG, isopropyl β -D-1-thiogalactopyranoside; K_D , dissociation constant; KDM, JmJC histone demethylase; LCMS, liquid chromatography–mass spectrometry; m^6A , N^6 -methyladenosine; m^6Am , N^6 -2'-O-dimethyladenosine; $6mA$, N^6 -methyldeoxyadenosine; m^3T , N^3 -methylthymidine; m^3U , N^3 -methyluridine; NAOX, nucleic acid oxygenase; NMR, nuclear magnetic resonance; 2OG, 2-oxoglutarate; PHD, hypoxia-inducible factor prolyl hydroxylase; Q-TOF, quadrupole time-of-flight; RFMS, Rapidfire mass spectrometry; SPE, solid-phase extraction; ssRNA, single-stranded RNA; TET, ten eleven translocation enzyme

REFERENCES

(1) Jia, G.; Fu, Y.; Zhao, X.; Dai, Q.; Zheng, G.; Yang, Y.; Yi, C.; Lindahl, T.; Pan, T.; Yang, Y.-G.; He, C. N^6 -Methyladenosine in

- 1468 Nuclear RNA Is a Major Substrate of the Obesity-Associated FTO. *Nat. Chem. Biol.* **2011**, *7*, 885–887.
- 1469 (2) Mauer, J.; Sindelar, M.; Despic, V.; Guez, T.; Hawley, B. R.;
1470 Vasseur, J.-J.; Rentmeister, A.; Gross, S. S.; Pellizzoni, L.; Debart, F.;
1471 Goodarzi, H.; Jaffrey, S. R. FTO Controls Reversible M6Am RNA
1472 Methylation during SnRNA Biogenesis. *Nat. Chem. Biol.* **2019**, *15*,
1473 340–347.
- 1474 (3) Gerken, T.; Girard, C. A.; Tung, Y.-C. L.; Webby, C. J.; Saudek,
1475 V.; Hewitson, K. S.; Yeo, G. S. H.; McDonough, M. A.; Cunliffe, S.;
1476 McNeill, L. A.; Galvanovskis, J.; Rorsman, P.; Robins, P.; Prieur, X.;
1477 Coll, A. P.; Ma, M.; Jovanovic, Z.; Farooqi, I. S.; Sedgwick, B.;
1478 Barroso, I.; Lindahl, T.; Ponting, C. P.; Ashcroft, F. M.; O'Rahilly, S.;
1479 Schofield, C. J. The Obesity-Associated FTO Gene Encodes a 2-
1480 Oxoglutarate-Dependent Nucleic Acid Demethylase. *Science* **2007**,
1481 *318*, 1469–1472.
- 1482 (4) Frayling, T. M.; Timpson, N. J.; Weedon, M. N.; Zeggini, E.;
1483 Freathy, R. M.; Lindgren, C. M.; Perry, J. R. B.; Elliott, K. S.; Lango,
1484 H.; Rayner, N. W.; Shields, B.; Harries, L. W.; Barrett, J. C.; Ellard, S.;
1485 Groves, C. J.; Knight, B.; Patch, A.-M.; Ness, A. R.; Ebrahim, S.;
1486 Lawlor, D. A.; Ring, S. M.; Ben-Shlomo, Y.; Jarvelin, M.-R.; Sovio, U.;
1487 Bennett, A. J.; Melzer, D.; Ferrucci, L.; Loos, R. J. F.; Barroso, I.;
1488 Wareham, N. J.; Karpe, F.; Owen, K. R.; Cardon, L. R.; Walker, M.;
1489 Hitman, G. A.; Palmer, C. N. A.; Doney, A. S. F.; Morris, A. D.;
1490 Smith, G. D.; Hattersley, A. T.; McCarthy, M. I. A Common Variant
1491 in the FTO Gene Is Associated with Body Mass Index and
1492 Predisposes to Childhood and Adult Obesity. *Science* **2007**, *316*,
1493 889–894.
- 1494 (5) Dina, C.; Meyre, D.; Gallina, S.; Durand, E.; Körner, A.;
1495 Jacobson, P.; Carlsson, L. M. S.; Kiess, W.; Vatn, V.; Lecoeur, C.;
1496 Delplanque, J.; Vaillant, E.; Pattou, F.; Ruiz, J.; Weill, J.; Levy-
1497 Marchal, C.; Horber, F.; Potoczna, N.; Hercberg, S.; Le Stunff, C.;
1498 Bougnères, P.; Kovacs, P.; Marre, M.; Balkau, B.; Cauchi, S.; Chèvre,
1499 J.-C.; Froguel, P. Variation in FTO Contributes to Childhood Obesity
1500 and Severe Adult Obesity. *Nat. Genet.* **2007**, *39*, 724–726.
- 1501 (6) Huff, S.; Tiwari, S. K.; Gonzalez, G. M.; Wang, Y.; Rana, T. M.
1502 M6A-RNA Demethylase FTO Inhibitors Impair Self-Renewal in
1503 Glioblastoma Stem Cells. *ACS Chem. Biol.* **2021**, *16*, 324–333.
- 1504 (7) Huang, Y.; Su, R.; Sheng, Y.; Dong, L.; Dong, Z.; Xu, H.; Ni, T.;
1505 Zhang, Z. S.; Zhang, T.; Li, C.; Han, L.; Zhu, Z.; Lian, F.; Wei, J.;
1506 Deng, Q.; Wang, Y.; Wunderlich, M.; Gao, Z.; Pan, G.; Zhong, D.;
1507 Zhou, H.; Zhang, N.; Gan, J.; Jiang, H.; Mulloy, J. C.; Qian, Z.; Chen,
1508 J.; Yang, C.-G. Small-Molecule Targeting of Oncogenic FTO
1509 Demethylase in Acute Myeloid Leukemia. *Cancer Cell* **2019**, *35*,
1510 677–691.
- 1511 (8) Li, Z.; Weng, H.; Su, R.; Weng, X.; Zuo, Z.; Li, C.; Huang, H.;
1512 Nachtergaele, S.; Dong, L.; Hu, C.; Qin, X.; Tang, L.; Wang, Y.;
1513 Hong, G.-M.; Huang, H.; Wang, X.; Chen, P.; Gurbuxani, S.;
1514 Arnovitz, S.; Li, Y.; Li, S.; Strong, J.; Neilly, M. B.; Larson, R. A.; Jiang,
1515 X.; Zhang, P.; Jin, J.; He, C.; Chen, J. FTO Plays an Oncogenic Role
1516 in Acute Myeloid Leukemia as a N6-Methyladenosine RNA
1517 Demethylase. *Cancer Cell* **2017**, *31*, 127–141.
- 1518 (9) Niu, Y.; Lin, Z.; Wan, A.; Chen, H.; Liang, H.; Sun, L.; Wang, Y.;
1519 Li, X.; Xiong, X.-f.; Wei, B.; Wu, X.; Wan, G. RNA N6-
1520 Methyladenosine Demethylase FTO Promotes Breast Tumor
1521 Progression through Inhibiting BNIP3. *Mol. Cancer* **2019**, *18*, 46.
- 1522 (10) Cui, Q.; Shi, H.; Ye, P.; Li, L.; Qu, Q.; Sun, G.; Sun, G.; Lu, Z.;
1523 Huang, Y.; Yang, C.-G.; Riggs, A. D.; He, C.; Shi, Y. M6A RNA
1524 Methylation Regulates the Self-Renewal and Tumorigenesis of
1525 Glioblastoma Stem Cells. *Cell Rep.* **2017**, *18*, 2622–2634.
- 1526 (11) Paris, J.; Morgan, M.; Campos, J.; Spencer, G. J.; Shmakova, A.;
1527 Ivanova, I.; Mapperley, C.; Lawson, H.; Wotherspoon, D. A.;
1528 Sepulveda, C.; Vukovic, M.; Allen, L.; Sarapuu, A.; Tavosanis, A.;
1529 Guitart, A. V.; Villacreces, A.; Much, C.; Choe, J.; Azar, A.; van de
1530 Lagemaat, L. N.; Vernimmen, D.; Nehme, A.; Mazurier, F.;
1531 Somervaille, T. C. P.; Gregory, R. I.; O'Carroll, D.; Kranc, K. R.
1532 Targeting the RNA m⁶A Reader YTHDF2 Selectively Compromises
1533 Cancer Stem Cells in Acute Myeloid Leukemia. *Cell Stem Cell* **2019**,
1534 *25*, 137–148.
- (12) Islam, M. S.; Leissing, T. M.; Chowdhury, R.; Hopkinson, R. J.;
1535 Schofield, C. J. 2-Oxoglutarate-Dependent Oxygenases. *Annu. Rev.*
1536 *Biochem.* **2018**, *87*, 585–620.
- (13) Macdougall, I. C.; Akizawa, T.; Berns, J. S.; Bernhardt, T.;
1537 Krueger, T. Effects of Molidustat in the Treatment of Anemia in
1538 CKD. *Clin. J. Am. Soc. Nephrol.* **2019**, *14*, 28–39.
- (14) Chen, H.; Cheng, Q.; Wang, J.; Zhao, X.; Zhu, S. Long-Term
1539 Efficacy and Safety of Hypoxia-Inducible Factor Prolyl Hydroxylase
1540 Inhibitors in Anaemia of Chronic Kidney Disease: A Meta-Analysis
1541 Including 13,146 Patients. *J. Clin. Pharmacol. Ther.* **2021**, *46*, 999.
- (15) Aik, W.; McDonough, M. A.; Thalhammer, A.; Chowdhury, R.;
1542 Schofield, C. J. Role of the Jelly-Roll Fold in Substrate Binding by 2-
1543 Oxoglutarate Oxygenases. *Curr. Opin. Struct. Biol.* **2012**, *22*, 691–700.
- (16) Thalhammer, A.; Aik, W.; Bagg, E. A. L.; Schofield, C. J. The
1544 Potential of 2-Oxoglutarate Oxygenases Acting on Nucleic Acids as
1545 Therapeutic Targets. *Drug Discovery Today: Ther. Strategies* **2012**, *9*,
1546 e91–e100.
- (17) Shishodia, S.; Zhang, D.; El-Sagheer, A. H.; Brown, T.;
1547 Claridge, T. D. W.; Schofield, C. J.; Hopkinson, R. J. NMR Analyses
1548 on N-Hydroxymethylated Nucleobases – Implications for Form-
1549 aldehyde Toxicity and Nucleic Acid Demethylases. *Org. Biomol. Chem.*
1550 **2018**, *16*, 4021–4032.
- (18) Fu, Y.; Jia, G.; Pang, X.; Wang, R. N.; Wang, X.; Li, C. J.;
1551 Smemo, S.; Dai, Q.; Bailey, K. A.; Nobrega, M. A.; Han, K.-L.; Cui,
1552 Q.; He, C. FTO-Mediated Formation of N6-Hydroxymethyladenosine
1553 and N6-Formyladenosine in Mammalian RNA. *Nat. Commun.* **2013**, *4*, 1798.
- (19) Toh, J. D. W.; Crossley, S. W. M.; Bruemmer, K. J.; Ge, E. J.;
1554 He, D.; Iovan, D. A.; Chang, C. J. Distinct RNAN-demethylation
1555 pathways catalyzed by nonheme iron ALKBH5 and FTO enzymes
1556 enable regulation of formaldehyde release rates. *Proc. Natl. Acad. Sci.*
1557 *U.S.A.* **2020**, *117*, 25284–25292.
- (20) Peng, S.; Xiao, W.; Ju, D.; Sun, B.; Hou, N.; Liu, Q.; Wang, Y.;
1558 Zhao, H.; Gao, C.; Zhang, S.; Cao, R.; Li, P.; Huang, H.; Ma, Y.;
1559 Wang, Y.; Lai, W.; Ma, Z.; Zhang, W.; Huang, S.; Wang, H.; Zhang,
1560 Z.; Zhao, L.; Cai, T.; Zhao, Y.-L.; Wang, F.; Nie, Y.; Zhi, G.; Yang, Y.-
1561 G.; Zhang, E. E.; Huang, N. Identification of Entacapone as a
1562 Chemical Inhibitor of FTO Mediating Metabolic Regulation through
1563 FOXO1. *Sci. Transl. Med.* **2019**, *11*, No. eaau7116.
- (21) Toh, J. D. W.; Sun, L.; Lau, L. Z. M.; Tan, J.; Low, J. J. A.;
1564 Tang, C. W. Q.; Cheong, E. J. Y.; Tan, M. J. H.; Chen, Y.; Hong, W.;
1565 Gao, Y.-G.; Woon, E. C. Y. A Strategy Based on Nucleotide Specificity
1566 Leads to a Subfamily-Selective and Cell-Active Inhibitor of N6-
1567 Methyladenosine Demethylase FTO. *Chem. Sci.* **2015**, *6*, 112–122.
- (22) Zheng, G.; Cox, T.; Tribbey, L.; Wang, G. Z.; Iacoban, P.;
1568 Booher, M. E.; Gabriel, G. J.; Zhou, L.; Bae, N.; Rowles, J.; He, C.;
1569 Olsen, M. J. Synthesis of a FTO Inhibitor with Anticonvulsant
1570 Activity. *ACS Chem. Neurosci.* **2014**, *5*, 658–665.
- (23) Wang, T.; Hong, T.; Huang, Y.; Su, H.; Wu, F.; Chen, Y.; Wei,
1571 L.; Huang, W.; Hua, X.; Xia, Y.; Xu, J.; Gan, J.; Yuan, B.; Feng, Y.;
1572 Zhang, X.; Yang, C.-G.; Zhou, X. Fluorescein Derivatives as
1573 Bifunctional Molecules for the Simultaneous Inhibiting and Labeling
1574 of FTO Protein. *J. Am. Chem. Soc.* **2015**, *137*, 13736–13739.
- (24) Huang, Y.; Yan, J.; Li, Q.; Li, J.; Gong, S.; Zhou, H.; Gan, J.;
1575 Jiang, H.; Jia, G.-F.; Luo, C.; Yang, C.-G. Meclofenamic Acid
1576 Selectively Inhibits FTO Demethylation of M6A over ALKBH5.
1577 *Nucleic Acids Res.* **2015**, *43*, 373–384.
- (25) Qiao, Y.; Zhou, B.; Zhang, M.; Liu, W.; Han, Z.; Song, C.; Yu,
1578 W.; Yang, Q.; Wang, R.; Wang, S.; Shi, S.; Zhao, R.; Chai, J.; Chang, J.
1579 A Novel Inhibitor of the Obesity-Related Protein FTO. *Biochemistry*
1580 **2016**, *55*, 1516–1522.
- (26) Aik, W.; Demetriades, M.; Hamdan, M. K. K.; Bagg, E. A. L.;
1581 Yeoh, K. K.; Lejeune, C.; Zhang, Z.; McDonough, M. A.; Schofield, C.
1582 J. Structural Basis for Inhibition of the Fat Mass and Obesity
1583 Associated Protein (FTO). *J. Med. Chem.* **2013**, *56*, 3680–3688.
- (27) Chen, B.; Ye, F.; Yu, L.; Jia, G.; Huang, X.; Zhang, X.; Peng, S.;
1584 Chen, K.; Wang, M.; Gong, S.; Zhang, R.; Yin, J.; Li, H.; Yang, Y.; Liu,
1585 H.; Zhang, J.; Zhang, H.; Zhang, A.; Jiang, H.; Luo, C.; Yang, C.-G.

- Development of Cell-Active N6-Methyladenosine RNA Demethylase FTO Inhibitor. *J. Am. Chem. Soc.* **2012**, *134*, 17963–17971.
- (28) Yan, L.; Colandrea, V. J.; Hale, J. J. Prolyl Hydroxylase Domain-Containing Protein Inhibitors as Stabilizers of Hypoxia-Inducible Factor: Small Molecule-Based Therapeutics for Anemia. *Expert Opin. Ther. Pat.* **2010**, *20*, 1219–1245.
- (29) McMurray, F.; Demetriades, M.; Aik, W.; Merkestein, M.; Kramer, H.; Andrew, D. S.; Scudamore, C. L.; Hough, T. A.; Wells, S.; Ashcroft, F. M.; McDonough, M. A.; Schofield, C. J.; Cox, R. D. Pharmacological Inhibition of FTO. *PLoS One* **2015**, *10*, No. e0121829.
- (30) Hopkinson, R. J.; Tumber, A.; Yapp, C.; Chowdhury, R.; Aik, W.; Che, K. H.; Li, X. S.; Kristensen, J. B. L.; King, O. N. F.; Chan, M. C.; Yeoh, K. K.; Choi, H.; Walport, L. J.; Thinnies, C. C.; Bush, J. T.; Lejeune, C.; Rydzik, A. M.; Rose, N. R.; Bagg, E. A.; McDonough, M. A.; Krojer, T. J.; Yue, W. W.; Ng, S. S.; Olsen, L.; Brennan, P. E.; Oppermann, U.; Müller, S.; Klose, R. J.; Ratcliffe, P. J.; Schofield, C. J.; Kawamura, A. 5-Carboxy-8-Hydroxyquinoline Is a Broad Spectrum 2-Oxoglutarate Oxygenase Inhibitor Which Causes Iron Translocation. *Chem. Sci.* **2013**, *4*, 3110–3117.
- (31) Woon, E. C. Y.; Demetriades, M.; Bagg, E. A. L.; Aik, W.; Krylova, S. M.; Ma, J. H. Y.; Chan, M.; Walport, L. J.; Wegman, D. W.; Dack, K. N.; McDonough, M. A.; Krylov, S. N.; Schofield, C. J. Dynamic Combinatorial Mass Spectrometry Leads to Inhibitors of a 2-Oxoglutarate-Dependent Nucleic Acid Demethylase. *J. Med. Chem.* **2012**, *55*, 2173–2184.
- (32) Woon, E. C. Y.; Tumber, A.; Kawamura, A.; Hillringhaus, L.; Ge, W.; Rose, N. R.; Ma, J. H. Y.; Chan, M. C.; Walport, L. J.; Che, K. H.; Ng, S. S.; Marsden, B. D.; Oppermann, U.; McDonough, M. A.; Schofield, C. J. Linking of 2-Oxoglutarate and Substrate Binding Sites Enables Potent and Highly Selective Inhibition of JmjC Histone Demethylases. *Angew. Chem., Int. Ed.* **2012**, *51*, 1631–1634.
- (33) Rose, N. R.; Ng, S. S.; Mecinović, J.; Liénard, B. M. R.; Bello, S. H.; Sun, Z.; McDonough, M. A.; Oppermann, U.; Schofield, C. J. Inhibitor Scaffolds for 2-Oxoglutarate-Dependent Histone Lysine Demethylases. *J. Med. Chem.* **2008**, *51*, 7053–7056.
- (34) Holt-Martyn, J. P.; Chowdhury, R.; Tumber, A.; Yeh, T.-L.; Abboud, M. I.; Lippl, K.; Lohans, C. T.; Langley, G. W.; Figg, W., Jr.; McDonough, M. A.; Pugh, C. W.; Ratcliffe, P. J.; Schofield, C. J. Structure-Activity Relationship and Crystallographic Studies on 4-Hydroxypyrimidine HIF Prolyl Hydroxylase Domain Inhibitors. *ChemMedChem* **2020**, *15*, 270–273.
- (35) England, K. S.; Tumber, A.; Krojer, T.; Scozzafava, G.; Ng, S. S.; Daniel, M.; Szykowska, A.; Che, K.; von Delft, F.; Burgess-Brown, N. A.; Kawamura, A.; Schofield, C. J.; Brennan, P. E. Optimisation of a Triazolopyridine Based Histone Demethylase Inhibitor Yields a Potent and Selective KDM2A (FBXL11) Inhibitor. *Medchemcomm* **2014**, *5*, 1879–1886.
- (36) Wagner, K. W.; Alam, H.; Dhar, S. S.; Giri, U.; Li, N.; Wei, Y.; Giri, D.; Cascone, T.; Kim, J.-H.; Ye, Y.; Multani, A. S.; Chan, C.-H.; Erez, B.; Saigal, B.; Chung, J.; Lin, H.-K.; Wu, X.; Hung, M.-C.; Heymach, J. V.; Lee, M. G. KDM2A Promotes Lung Tumorigenesis by Epigenetically Enhancing ERK1/2 Signaling. *J. Clin. Invest.* **2013**, *123*, S231–S246.
- (37) Lu, D.-H.; Yang, J.; Gao, L.-K.; Min, J.; Tang, J.-M.; Hu, M.; Li, Y.; Li, S.-T.; Chen, J.; Hong, L. Lysine Demethylase 2A Promotes the Progression of Ovarian Cancer by Regulating the PI3K Pathway and Reversing Epithelial-mesenchymal Transition. *Oncol. Rep.* **2019**, *41*, 917–927.
- (38) Leung, I. K. H.; Demetriades, M.; Hardy, A. P.; Lejeune, C.; Smart, T. J.; Szöllösi, A.; Kawamura, A.; Schofield, C. J.; Claridge, T. D. W. Reporter Ligand NMR Screening Method for 2-Oxoglutarate Oxygenase Inhibitors. *J. Med. Chem.* **2013**, *56*, 547–555.
- (39) Chowdhury, R.; Candela-Lena, J. I.; Chan, M. C.; Greenald, D. J.; Yeoh, K. K.; Tian, Y.-M.; McDonough, M. A.; Tumber, A.; Rose, N. R.; Conejo-Garcia, A.; Demetriades, M.; Mathavan, S.; Kawamura, A.; Lee, M. K.; van Eeden, F.; Pugh, C. W.; Ratcliffe, P. J.; Schofield, C. J. Selective Small Molecule Probes for the Hypoxia Inducible Factor (HIF) Prolyl Hydroxylases. *ACS Chem. Biol.* **2013**, *8*, 1488–1496.
- (40) Hillringhaus, L.; Yue, W. W.; Rose, N. R.; Ng, S. S.; Gileadi, C.; Loenarz, C.; Bello, S. H.; Bray, J. E.; Schofield, C. J.; Oppermann, U. Structural and Evolutionary Basis for the Dual Substrate Selectivity of Human KDM4 Histone Demethylase Family*. *J. Biol. Chem.* **2011**, *286*, 41616–41625.
- (41) Han, Z.; Niu, T.; Chang, J.; Lei, X.; Zhao, M.; Wang, Q.; Cheng, W.; Wang, J.; Feng, Y.; Chai, J. Crystal Structure of the FTO Protein Reveals Basis for Its Substrate Specificity. *Nature* **2010**, *464*, 1205–1209.
- (42) Zhang, X.; Wei, L.-H.; Wang, Y.; Xiao, Y.; Liu, J.; Zhang, W.; Yan, N.; Amu, G.; Tang, X.; Zhang, L.; Jia, G. Structural Insights into FTO's Catalytic Mechanism for the Demethylation of Multiple RNA Substrates. *Proc. Natl. Acad. Sci. U.S.A.* **2019**, *116*, 2919–2924.
- (43) Chowdhury, R.; McDonough, M. A.; Mecinović, J.; Loenarz, C.; Flashman, E.; Hewitson, K. S.; Domene, C.; Schofield, C. J. Structural Basis for Binding of Hypoxia-Inducible Factor to the Oxygen-Sensing Prolyl Hydroxylases. *Structure* **2009**, *17*, 981–989.
- (44) Chowdhury, R.; Leung, I. K. H.; Tian, Y.-M.; Abboud, M. I.; Ge, W.; Domene, C.; Cantrelle, F.-X.; Landrieu, I.; Hardy, A. P.; Pugh, C. W.; Ratcliffe, P. J.; Claridge, T. D. W.; Schofield, C. J. Structural Basis for Oxygen Degradation Domain Selectivity of the HIF Prolyl Hydroxylases. *Nat. Commun.* **2016**, *7*, 12673.
- (45) Yeh, T.-L.; Leissing, T. M.; Abboud, M. I.; Thinnies, C. C.; Atasoylu, O.; Holt-Martyn, J. P.; Zhang, D.; Tumber, A.; Lippl, K.; Lohans, C. T.; Leung, I. K. H.; Morcrette, H.; Clifton, I. J.; Claridge, T. D. W.; Kawamura, A.; Flashman, E.; Lu, X.; Ratcliffe, P. J.; Chowdhury, R.; Pugh, C. W.; Schofield, C. J. Molecular and Cellular Mechanisms of HIF Prolyl Hydroxylase Inhibitors in Clinical Trials. *Chem. Sci.* **2017**, *8*, 7651–7668.
- (46) Figg, W. D., Jr.; McDonough, M. A.; Chowdhury, R.; Nakashima, Y.; Zhang, Z.; Holt-Martyn, J. P.; Krajnc, A.; Schofield, C. J. Structural Basis of Prolyl Hydroxylase Domain Inhibition by Molidustat. *ChemMedChem* **2021**, *16*, 2082.
- (47) Aguilar, J. A.; Nilsson, M.; Bodenhansen, G.; Morris, G. A. Spin Echo NMR Spectra without J Modulation. *Chem. Commun.* **2012**, *48*, 811–813.
- (48) Otwinowski, Z.; Minor, W. [20] Processing of X-ray diffraction data collected in oscillation mode. *Macromolecular Crystallography Part A*; Academic Press, 1997; Vol. 276, pp 307–326.
- (49) Winter, G. Xia2: An Expert System for Macromolecular Crystallography Data Reduction. *J. Appl. Crystallogr.* **2010**, *43*, 186–190.
- (50) McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R. J. Phaser Crystallographic Software. *J. Appl. Crystallogr.* **2007**, *40*, 658–674.
- (51) Liebschner, D.; Afonine, P. V.; Baker, M. L.; Bunkóczi, G.; Chen, V. B.; Croll, T. I.; Hintze, B.; Hung, L.-W.; Jain, S.; McCoy, A. J.; Moriarty, N. W.; Oeffner, R. D.; Poon, B. K.; Prisant, M. G.; Read, R. J.; Richardson, J. S.; Richardson, D. C.; Sammito, M. D.; Sobolev, O. V.; Stockwell, D. H.; Terwilliger, T. C.; Urzhumtsev, A. G.; Videau, L. L.; Williams, C. J.; Adams, P. D. Macromolecular Structure Determination Using X-Rays, Neutrons and Electrons: Recent Developments in Phenix. *Acta Crystallogr., Sect. D: Struct. Biol.* **2019**, *75*, 861–877.
- (52) Shishodia, S.; Schofield, C. J. Improved Synthesis of Phosphoramidite-Protected N6-Methyladenosine via BOP-Mediated SNAr Reaction. *Molecules* **2021**, *26*, 147.